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Abstract
Multiple sclerosis (MS) is a chronic pathology of the central nervous system,
characterized by inflammation, demyelination and neurodegeneration. The prevalence
and incidence rates of MS are on the rise worldwide. What causes MS is unknown.
However, it is widely accepted that MS occurs in genetically susceptible individuals
exposed to certain environmental factors. Sero-epidemiological data suggest a strong
association between Epstein-Barr virus (EBV) and MS. EBV is one of the commonest
viruses in the human population with ~90% global seropositivity. EBV infects naive
B cells and immortalizes them. While some postmortem studies have shown EBV in
MS lesions, others have failed to reach similar observation. Variation in technical
approaches and sample size could be the reason for reported inconsistencies. Thus, we
have assessed the hypothesis that EBV may enter MS brain and contribute to disease
pathogenesis. Four objectives were highlighted in this thesis: to investigate EBV
presence in MS brain using large sample size, quantify EBV viral load in brain tissues,
determine possible route of virus entry to the brain, and determine viral gene
expression in MS brain. In a case-control design, 122 MS and non-MS cases were
studied and compared. Formalin stored brain coronal slices were received from Rocky
Mountain MS Centre, US. DNA extraction was optimized and PCR amplification of
EBV BamHI was performed to determine EBV presence/ absence in the brain. EBV
viral load was quantified in infected cases using qPCR. Localization of infected cells
was achieved using EBER in situ hybridization, and viral gene expression was
determined using immunohistochemistry. The phenotype of EBV infected cells was
characterized using immunohistochemistry for cellular markers. EBV DNA was
detected in 90% MS and 24% non-MS cases. EBV infected cells were more prevalent
in brain parenchyma than in meninges, expressing latent EBNA1 and lytic BZLF1.
EBV infected cells were likely to have B lymphocyte phenotype. We concluded that
EBV differential presence in MS brain reflected a pathogenic contribution to MS.
Further studies are warranted to determine the mechanism of EBV involvement in MS
pathogenesis.

Keywords: Multiple sclerosis pathogenesis, environmental risk factors, Epstein-Barr
virus, viral gene expression, archival formalin preserved brain tissues, B lymphocytes.
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)Title and Abstract (in Arabic

دور فيروس ابشتاين بار في التسبب في مرض التصلب المتعدد
الملخص
التصلب العصبي المتعدد عبارة عن مرض مزمن يصيب الجهاز العصبي المركزي ويتميز بااللتهاب وضمور
في طبقة الميالين والتنكس العصبي .معدالت انتشار التصلب العصبي المتعدد في تزايد على مستوى العالم .والسبب
المؤدي الى حدوث المرض غير معروف .اال أنه من المتعارف عليه أنه يحدث في األفراد ذوالقابلية الوراثية عن
طريق التعرض لبعض العوامل البيئية .تقترح بيانات وبائية مصلية بأن هناك عالقة قوية بين فيروس ابشتاين بار
والتصلب العصبي المتعدد .يعد فيروس ابشتاين بار واحدا من الفيروسات الشائعة في اإلنسان ،حيث أنه %90
من سكان العالم مصابون به .يصيب الفيروس خاليا (ب) ويساعد على بقائها .بينما أظهرت بعض الدراسات
وجود فيروس ابشتاين بار في األعضاء المتضررة بالتصلب العصبي المتعدد ،إالّ ّ
أن دراسات أخرى أخفقت في
الوصول لمالحظات مشابهة .من الممكن أن يكون اإلختالف في النهج – األساليب التقنية وحجم العينة سبب هذه
التناقضات .ولذلك قمنا بتقييم فرضية بأنه من الممكن أن يدخل فيروس ابشتاين بار إلى الدماغ المصاب بالتصلب
العصبي المتعدد وبالتالي يساهم في تطوير (التسبب لحدوث) المرض .ومن هنا تم تسليط الضوء على أربعة
أهداف بخصوص هذه األطروحة :التحقق من وجود فيروس ابشتاين بار في الدماغ المصاب بالتصلب العصبي
المتعدد وذلك باستخدام عينة كبيرة ،وإحصاء تجمعات الفيروس في خاليا الدماغ ،وتحديد السبل التي من الممكن
أن تؤدي الى دخول الفيروس إلى الدماغ ،وكذلك تحديد الجينات الفيروسية في الدماغ المصاب بالتصلب العصبي
المتعدد .تمت دراسة ومقارنة  122حالة مصابة وغير مصابة بالمرض .وذلك باستخدام شرائح من الدماغ والتي
تم تخزينها في محلول الفورمالين ،تم استالمها من مركز روكي ماونتن للتصلب العصبي المتعدد ،الواليات
المتحدة األمريكية .و تم تنفيذ اختبار تفاعل البلمرة المتسلسل لتحديد وجود الفيروس في الدماغ من عدمه .باإلضافة
الى إحصاء التجمع الفيروسي من الحاالت المصابة وذلك باستخدام تفاعل البلمرة المتسلسل .ومن ث ّم ت ّم التوصل
إلى الخاليا المصابة باستخدام  EBERفي موقع التهجين ،وكما تم تحديد الجينات الفيروسية عن طريق استخدام
الكيمياء المناعية .و لقد تم اكتشاف الحمض النووي للفيروس في  %90في الحاالت المصابة بالتصلب العصبي
المتعدد و  %24في الحاالت الغير مصابة بالمرض .كانت الخاليا المصابة بالفيروس أكثر انتشارا في حمة الدماغ
عنه مما كانت عليه في السحايا .لقد استخلصنا أن الفيروس الموجود في الخاليا المصابة تعكس مدى مساهمة
الفيروس في المرض .هناك حاجة للمزيد من الدراسات لتوضيح مدى و كيفية مساهمة الفيروس في المرض.

مفاهيم البحث الرئيسية :التصلب العصبي المتعدد ،عوامل الخطر البيئية ،فيروس ابشتاين بار،الجينات
الفيروسية ،أنسجة المخ المحفوظة في الفورمالين ،خاليا (ب) الليمفاوية
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Chapter 1: Introduction
1.1 Overview
Myelin sheaths are the lipid-rich covers surrounding axons, and formed by
oligodendrocytes in the central nervous system (CNS), and Schwann cells in the
peripheral nervous system (PNS). Myelination of nerve fibers has a significant
importance in speeding up the dissemination of electrical impulse and saving energy
needed to depolarize axonal membrane during the so-called ‘saltatory conduction’ of
electrical impulse. Severely injured myelin sheaths can decelerate impulse
conductance which ultimately can impair affected axonal tracts [1].
Damage to myelin can be mainly in the form of loss of pre-existing myelin
(known as demyelination) or deficiency in myelin genesis by precursor cells (known
as dysmyelination). Demyelination can occur in the CNS and PNS. CNS
demyelinating diseases arise from a wide array of factors, including ischemic/ hypoxic
injury, focal compression, viral infection, acquired and inherited metabolic disorders,
and unusual inflammatory response [2]. The most prevalent demyelinative disease of
all and the number one cause of neurological (non-traumatic) disability in young adults
worldwide [2, 3] is multiple sclerosis (MS).
In MS, prolonged inflammation and extensive loss of myelin around variably
well-maintained axons disturb the integrity of the white matter in the brain and spinal
cord. Multiple focal demyelinating lesions, known as plaques, are formed. Plaques are
an essential characteristic of MS [4]. Plaque activity usually serves as the clinical
substrate of ostensible disability [5], which varies in magnitude and type between
patients depending on location, size, number and activity of plaque burden, and CNS
tissue atrophy [6]. MS commonly impacts posterior visual pathways [7].

2

Fatigue, weakness of limbs, hemiplegia and paraplegia, thermo-sensitivity,
optic neuritis and partial or total loss of vision, gait problems, ataxia, decreased
cognitive capacity such as difficulty in recognizing and solving problems and
decreased information processing skills, are some of the frequent symptoms seen in
patients with MS [8]. Less common clinical manifestations are seizures and cortical
deficits such as aphasia, apraxia and agnosia [7] (figure 1.1). Disability resulting from
disease progression does not directly cause the death of MS patients [9] but MS
patients carry an elevated risk of all-cause mortality ranging between 1.7 [10] and 3.5
fold higher than general population [11].

Figure 1.1: Most common symptomology of MS. Data is according to latest update
of Atlas of MS. Adapted from MSIF, MS Atlas 2013
Disability caused by MS, in most cases, accumulates, progresses till it reaches
irreversibility threshold and thus worsening of symptoms, all of which make MS a
huge socioeconomic burden [12]. Disease symptoms require continuous monitoring
and management, as more than half of MS patients will need aid with movement in
about 2 decades after disease onset. The majority of individuals afflicted by MS are of
working age yet disability renders them unemployed [13, 14]. Two questionnaires
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distributed in 2003 and 2007, by the Australian Multiple Sclerosis Longitudinal Study
showed a total 5.4% decrease in part- and full-time employment in the MS population.
This notable loss of employment was commonly attributed, by respondents, to MSrelated fatigue, difficulty in moving limbs and mobility, cognitive problems such as
struggle in concentration and remembering tasks, and difficulty in maintaining balance
of posture. This is one aspect of the impact of MS on the quality of life (socioeconomic status) of MS patients [14].
1.2 Clinical Subtypes
Clinical course of MS follows two distinct phases, the phase of discontinuous
attacks, known as relapsing-remitting (RR) and the phase of uninterrupted progressive
deterioration [4]. MS is initiated in the majority (~90%) of patients in the form of
RRMS [15]. Most patients who are proven to harbor a form of inflammatory CNS
demyelinating disease after they have undergone CNS diagnostic biopsy are found to
suffer from RRMS [16]. RRMS usually starts with serious sudden deficit(s) [15]
persisting from a day to weeks [17, 18]. From this point onwards, the disease course
becomes unpredictable and patients suffer from uncertainties regarding their fate. No
single patient suffers the exact same symptoms the same way and the same severity
for the same period of time as another does. A complete or incomplete recovery
follows the symptom(s), thus the name relapsing-remitting [6, 19].
The term clinically isolated syndrome (CIS) is introduced to describe those
initial MS symptoms that suddenly appear and suddenly go away [18]. CIS can occur
as a severe acute form of disability or trivial symptoms that some patients may ignore
to seek medical care for [6]. More than half of CIS patients have white matter lesions
on their magnetic resonance imaging (MRI) scans. These lesions in about 80% of
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patients remain clinically silent for 20 years before they become symptomatic resulting
in either RR course or progressive course [18].
It takes ~15-25 years for RRMS patients to harbor sufficient irreversible
damage, and permanent disability with little or no recovery in between manifests [17].
This is called secondary progressive (SP) MS [20]. Because SPMS is characterized
with gradual exacerbation of disability, up to 60% of SPMS patients end up with
ambulatory hardship, rendering them functionally restricted and unemployed [19].
In a small subset of patients, MS is initiated with a progressive course, in which
disease symptoms are continuously worsening from day one of the first attack. There
is hardly any remissions taking place. This is called primary progressive (PP) MS [19,
21]. When the progressive course is accompanied by one or more acute relapses, MS
is called relapsing progressive (RP) [19] (figure 1.2).
Very rarely, MS disease activity starts with an acute aggressive phase that lasts
till the death of the patient, within almost a year from disease onset. This defines acute
MS [21].

Figure 1.2: Distribution of most prevalent clinical subtypes of MS. Adapted from
MSIF, MS Atlas 2013
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1.3 Diagnosis
Many of the symptoms experienced by MS patients are non-specific and can
point to several other possible ailments, such as CNS tumors, systemic vasculitis
involving the CNS, and hereditary cerebellar ataxia [20]. Therefore, MS diagnosis is
made upon a combination of clinical and auxiliary para-clinical evidences collectively
termed the McDonald criteria [6, 20]. McDonald criteria are based on one elementary
condition that is providing an indication of both temporal and spatial dissemination of
white matter lesions [22]. Besides MS-suggestive clinical symptoms, radiologic
evidence, mainly MRI scans, could support MS diagnosis [22]. Although white matter
abnormalities shown on MRI scans are not disease-specific, MRI has a great sensitivity
in detecting lesions in up to 95% of MS patients. Demyelination is recognized on MRI
as small empty bright or dark spots that lie vertically on the axis of the lateral ventricles
[21]. Specificity of MRI is albeit less than its sensitivity. For instance, the non-specific
‘normal’ MRI brain lesions appearing after the 5th decade of life can resemble MS
lesions [20]. Integrating intravenous administration of the heavy metal gadolinium
(Gd) with MRI scans can reveal focal inflammatory lesions with current activity.
Active lesions are usually associated with temporarily collapsed blood-brain barrier
(BBB), which allows the influx of the heavy metal into plaque-affected areas of the
CNS (figure 1.3) [19].

6

Figure 1.3: Focal active lesions. MRI scan shows Gd-enhancing lesions suggestive of
BBB disruption [19]
Other tests such as evoked potentials in the visual (VEPs), somatosensory and
auditory pathways and analysis of cerebrospinal fluid (CSF) can also be used in
diagnosing difficult cases with insidious activity (figure 1.4) [22, 23]. Every 9 out of
10 MS patients have elevated production of immunoglobulins and multiple distinct
IgG oligoclonal bands (OCBs) in their CSF [19, 20, 23]. These observations are
pathologically non-specific, but they can confirm MRI-based evidence of MS [23].
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Figure 1.4: McDonald criteria of MS. In RRMS, minimum of two separate evident
clinical episodes (dissemination in time and space) can, with no additional tests,
establish the diagnosis of MS (top panel). When only a single clinical event is
objectively evident, MRI scan showing a Gd-enhancing lesion can be sufficient to
establish MS diagnosis (middle panel). To establish MS diagnosis in PPMS course,
persistent clinical symptoms should be confirmed by MRI brain and spinal cord
lesions together with intrathecal IgG synthesis (IgG OCBs) (bottom panel) [20]
1.4 Epidemiology of MS
The foundation of epidemiology of an ailment is that it does not take place
randomly but in patterns. The observed patterns may, in one way or another, suggest
the maneuver of the underlying causes, and probably shape the distribution of risk
factors [24]. The fast accumulating epidemiological studies of MS has formed massive
repositories of data of MS prevalence and incidence. However, the meta-analytic
compilation of these studies reveal some sort of variability. First, the population under
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observation differs from one study to another in sample size, age range, ethnicity,
composition of the sample, and the amount of public awareness of MS as a disease.
Second, there is an inconsistency between studies in the ability of recognizing and
including benign MS cases. This may result from the highly variable disease latency
period at which MS ascertainment could be difficult. Accessibility to appropriate
medical expertise in MS including MS specialized neurologists, MS diagnostic tools
and modified criteria and consistency level of interpretation of results obtained from
MS tests, indirectly impacts incidence rates in a given population [25, 26].
The fact that MS has a complex component of interactions between genes and
environment has complicated the epidemiological norms of MS. This has been evident
in migration studies. Factors, such as distance from the equator (i.e. latitudinal effect),
ethnicity, and migration from low- to high-risk region during or before adolescence,
have moulded distribution of MS cases in a unique pattern that is far from being
globally even (figure 1.5) [27].
Worldwide, the incidence of MS ranges from 0.5 to 20.6 per 100,000
individuals annually. This incidence rate has resulted in a prevalence that ranges from
5 to 335 per 100,000 individuals with disease lasting between 7 and 36 years [28].
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Figure 1.5: Distribution of MS worldwide. Prevalence rates are according to the
latest update of reports collected by Multiple Sclerosis International Federation
(MSIF) [29]
World Health Organization (WHO) and Multiple Sclerosis International
Federation (MSIF) put a huge effort in gathering data from 112 countries (~87% of the
world) (figure 1.5) to update the most comprehensive atlas of MS epidemiological
parameters in 2013 (mapping Multiple sclerosis around the world). The atlas revealed
a notable increase in the global prevalence of MS reaching to 2.3 million people, partly
in response to improved MS-oriented services such as MS-expert neurologists and
MRI machines that support diagnostic accuracy [29, 30]. The increase in MS burden
has led to an intense need for searching for causes of the disease and effective therapies
[31].
Despite variations in MS distribution between different continents and between
different regions within one continent [27], MS appears to have a predilection to the
north. MS prevalence decreases as you approach the equator. However, the latitudinal
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gradient seems to diffuse in some regions, such as the US, where new patterns of MS
distribution have been reported [28, 32].
Although MS prevalence seems to be on rise, it does not accurately reflect the
level of MS risk. Increased MS prevalence is partly due to the increased life expectancy
of MS patients due to improved health care services and disease management.
Therefore, rate of incidence of new cases may be more accurate in reflecting the level
of MS risk. The incidence of MS is increasing, and in many regions is thought to reflect
a true increase mainly due to increased incidence in females. Hence, increased femaleto-male sex ratios. In Iran, for instance, this ratio has drastically peaked to 3.12:1 [33].
Similar observation has been reported in the US [34]. The most reliable data proving
such bias comes from the national Danish MS registry [27, 35]. Also, MS prevalence
and incidence show bias towards certain age groups and ethnicities. In the US, MS
prevalence peaks in the age category of 45-49 years [34]. A US military study has
reported higher incidence of MS in blacks compared to whites [28].
Furthermore, MS distribution is affected by migration patterns. A recent study
from Norway [36] has showed that Iranian immigrants appear to acquire high MS risk
that is similar in magnitude to what native Norwegians face, but higher than the risk
that Iranians face while residing in Iran (country of origin) [36]. This implies the role
for an environmental component in elevating MS risk. Similarly, higher MS
prevalence has been noted in second generation Pakistanis compared to their first
generation immigrants in Norway [36]. These data support the notion that MS risk
rises when migrating from a low-risk area to a high-risk area [37]. Nonetheless, this
effect does not seem to apply to certain ethnicities such as Vietnamese immigrants to
Norway, indicating impact of genetics in protecting from or predisposing to MS [36].
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MS epidemiological studies are lacking from the Middle East and North Africa
(MENA) region. In general, prevalence of MS in MENA countries has been estimated
to be around 50 per 100,000 individuals (ranging from 14.77 (Kuwait, 2000) to 101.4
(Turkey, 2006) per 100,000 individuals) [38]. However, these data do not provide
distinction of MS distribution between Arabs and non-Arab races (such as Berbers,
Kurds and Black Africans) living in MENA [31]. Available data from Kuwait have
shown an increasing trend in the incidence of MS [39]. In the UAE, latest data shows
that MS annual incidence rate has increased to 7 per 100,000 individuals per year [40].
Overall, there seems an upward shift in both MS incidence and prevalence in the Gulf
countries. Studies that monitor and look for reasons for this shift are needed.
1.5 Pathology of MS Plaques
Pathologically MS possesses four intermingling aspects, 1) inflammatory
feature which may or may not be the primary event involving different cellular and
humoral immune participants, 2) dynamic demyelination of axons, 3) axonal injury
that is partially resolved by limited CNS repair capacity but eventually progresses to
varying levels of axonal loss (30-80% loss [41]), and 4) astrogliosis. Each one of these
aspects can be manifested in the clinical course of MS. For instance, transient BBB
breakdown and subsequent influx of inflammatory cells into the brain’s active lesion
link to a new episode of symptoms, while irreversible disability reflects axonal loss
that is beyond brain’s capacity to repair [42].
Overall, plaques in MS brain could be very heterogeneous in respect to amount
of inflammation, expansion of demyelination, capacity to re-myelinate and extent of
damage to axons. [5]. Formation of focal acute lesions depend on dynamic breakdown
of myelin by numerous immune cells. Acute plaques are poorly-demarcated
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edematous regions. T cells, monocytes and lipid-laden ‘foamy’ macrophages all
contribute to peeling myelin off of axons, resulting in apoptosis of oligodendrocytes,
reactive gliosis, and formation of perivascular cuffs (inflamed blood vessels) [5].
As time passes, most of acute plaques turn into chronic well-demarcated
regions. Immune infiltration subsides in chronic lesions, and myelin loss becomes
apparent. Accumulation of myelin loss and diminished axons give chronic plaques a
distinct gross appearance of translucent color-faded areas [5]. Axonal loss can spread
beyond the borders of MS lesions, reaching to areas known as the normal-appearing
white matter, and normal appearing gray matter [42].
Based on histological and immunohistochemical staining, MS white matter
plaques are differentiated into early and late active lesions, smoldering or slowly
expanding lesions, inactive lesions, and completely remyelinated lesions (shadow
plaques). Active lesions have a compact content of macrophages engulfing vacuoles
of various myelin debris indicating current activity of the lesion. In smoldering lesions,
the center lacks myelin destruction activity, but surrounded by a fence (rim) of
activated microglia [3]. Whereas inactive lesions are sharply demarcated areas lacking
any noticeable activity of myelin degradation. Lastly, remyelinated shadow plaques
are well-defined areas, marked by substantial fibrillary gliotic scar formation, which
is histologically revealed by increased staining for GFAP (glial fibrillary acidic
protein). Fully remyelinated plaques are found to be the most vulnerable sites for
second episode of myelin destruction [3].
Although MS definition gives the impression that it is mainly a white matter
disease, yet the occurrence of diffuse injury in the grey matter is common and can
happen as early as the onset of first MS attack. Grey matter plaques are frequently seen
in progressive MS [5, 43]. They are MS-specific pathology, because other neurological
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diseases do not show such feature [41]. Unlike white matter lesions, cortical lesions
do not associate with BBB breakdown or influx of immune cells [41], hence their poor
detectability in MRI scans [44]. Grey matter damage usually takes the form of
irreparable extensive loss of neurons [45] and nerve transection resulting in
neurodegeneration [5]. Clinically this can be translated into irreversible disability [46].
Established myelin histochemical stains such as Luxol fast blue (LFB) and oil red O,
seem to have inadequate sensitivity to reveal grey matter demyelination. In contrast to
these stains, using myelin basic protein (MBP) immunohistochemistry has been
relatively successful in showing deep cortical lesions [44]. It has been found that
subpial cortical lesions are crowned by inflamed meninges that carry several
aggregates of lymphocytes similar in structure to ectopic B cell follicles. In progressive
MS, presence of ‘B cell follicle-like’ structures seem to accelerate disease course [5].
Meningeal lymphocyte aggregates and CSF are suggested to harbor soluble factors
that signals pathological events leading to cortical lesion formation [41, 47].
1.6 Immunopathogenesis of MS
A collection of data from genetic, immunological, and histopathological
studies strongly support the involvement of the immune system in the pathogenesis of
MS [41]. The CNS, however, lacks the lymphatic system as we know it, and major
histocompatibility complex (MHC) class I and class II molecules are far from being
constitutively expressed by cells in the CNS parenchyma. This, in the past, led to the
belief that the CNS is excluded from immunosurveillance [48]. The notion of the CNS
being an immune privileged site has been substituted with a more accurate term
‘immune specialized site’ to accommodate the highly cautious immune response to
any given insult within the CNS [49].
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Under physiological conditions, CSF drain occurs in certain anatomical spaces
open for immune surveillance by lymphocytes. CSF drain, collected in the
leptomeningeal space, carries ‘CNS-accessed’ antigens all the way to the cervical
lymph nodes, where recirculating lymphocytes encounter their antigens [49]. Immune
surveillance of the CNS is partly regulated by the CSF-producing choroid plexus, a
highly vascularized element within the ventricles. Choroid plexus is made up of a layer
of epithelial cells connected by tight junctions on the surface facing the CSF medium.
This feature qualifies choroid plexus to guard the integrity and enhance protection of
BBB. The epithelial layer of the choroid plexus surrounds fenestrated blood vessels
located within choroid plexus parenchyma (figure 1.6), forming blood-CSF barrier (BCSF-B). B-CSF-B may be a route for lymphocytes extravasation into the brain [48].
The established correlation between frequency of (inflammatory) lymphocytes
within the CSF and lesion load in the MS brain implies a role for B-CSF-B in
controlling the exchange taking place between the circulation and the CSF. In MS,
expression of tight junctions between epithelial cells of the choroid plexus is deficient,
thus increased likelihood of inflow of leukocytes to the CSF compartment [48].
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Figure 1.6: Choroid plexus structure in healthy brain and MS. Choroid plexus is
made up of a stretch of epithelial cells that surround fenestrated blood vessels which
are located within the parenchyma of choroid plexus. In healthy controls (left
panel), leukocytes can flow into the parenchyma where they encounter resident
APC. Regardless of the results of this encounter, leukocytes do not cross through
the tight junctions of choroid plexus epithelia which serve as a form of BBB by
developing B-CSF-B. However, this barrier is, somewhat, dysfunctional under
inflammatory conditions such as MS (right panel) and lymphocytes that may be
potentially activated, flow into the CSF where a cascade of inflammatory events
ensue [48]
On the other hand, the BBB endothelial layer is supported by feet of astrocytes
(figure 1.7). Astrocytes make cell-to-cell interaction with local roaming microglia,
other nearby astrocytes, and myelin-generating oligodendrocytes. Under a stressful
event like MS, astrocytes tend to retract their feet processes from endothelial layer,
compromising BBB integrity [50]. Moreover, reactive astrocytes in MS maintain
production of inflammatory cytokines and chemokines, inviting numerous immune
cells to the brain. It is unclear whether reactivation of astrocytes results from BBB
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disruption early in MS or due to some other unidentified pathophysiological alterations
in astrocytes ambiance [48].

Figure 1.7: Perivascular astrocytes support BBB. They stretch and press their
endfeet towards BBB endothelial basement membrane which encloses endothelial
cells and pericytes. Besides this mechanical support to the BBB, astrocytes maintain
an interaction with adjacent astrocyte and surveilling microglia [51]
For long time MS has been thought to be orchestrated mainly by CD4+ T cells.
This notion has been formulated into the mouse model of human MS, namely
experimental autoimmune encephalomyelitis (EAE), developed through active
immunization of susceptible animals with an emulsion of CNS homogenate, myelin or
its derivatives [42], or through adoptive transfer of CD4+ T cells specific to myelin
antigens [50]. This model has yielded massive amount of information about disease
pathogenesis especially in terms of the role of different T cell subsets in
neuroinflammation [52]. Two main subsets of CD4+ T cells are greatly involved in
promoting inflammation in MS, T helper-1 (Th1) and T helper-17 (Th17) [41].
A small proportion of CD4+ T cells reactive to myelin auto-antigens is capable
of escaping deletion during thymic negative selection. These autoreactive CD4+ T cells
are detectable in the periphery under healthy conditions. Importantly, frequency of
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peripheral autoreactive CD4+ T cells is found unaltered during MS disease. As
opposed to blood of healthy controls, the surviving population of myelin-specific
CD4+ T cells in MS circulation produces increased levels of pro-inflammatory
interleukin-17 (IL-17), interferon–gamma (IFN-γ) and granulocyte-macrophage
colony-stimulating factor (GM-CSF) [53, 54], and appear unaffected by immune
checkpoints imposed by regulatory T cells (Tregs), which normally down-regulate the
activity of inflammatory subsets of T cells [48]. In MS lesions and CSF, increased
proportions of CD4+ T cells and CD8+ T cells are generated by clonal expansion,
indicating that T cell activity in MS happens in antigen-specific fashion [55]. Selfantigens that trigger autoimmune response in MS remain largely unidentified [41].
There is also clonal expansion in B cell population in MS lesions with
specificity for axonal antigens [50]. The role served by B cells is believed to involve
antigen processing and presentation, and subsequent release of myelin-reactive
antibodies [56]. Autoantibodies secreted by plasma cells can bind oligodendrocytes
and signal complement activation to induce myelin destruction [41]. The large fraction
of B lymphocytes and plasma cells in MS lesions, meninges and CSF seem sustained
partly by glia-derived cytokines and endogenous survival signals [12].
CNS-resident microglia is another immune cell subset playing a role in MS
immunopathogenesis. The neuroinflammatory stress taking place in MS lesions
stimulate activation of microglia. In response to pathological activation, microglia
multiply with increased expression of MHC molecules, and generate various
inflammatory cytokines and reactive oxygen species (ROS). They also functionally
switch into phagocytic cells [50]. Other prevalent innate immune cells are monocytederived macrophages. Together with activated microglia, macrophages can either
directly induce inflammation and tissue injury on their own or indirectly through
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communication with adaptive immune cells. To directly cause tissue injury, microglia
and macrophages serve as phagocytes that destroy myelin sheaths around axons and
damage naked axons [57].
Due to the substantial contribution of the immune system to MS pathogenesis,
several disease-modifying treatments (DMTs) used in MS are immunosuppressive or
immunomodulatory. Generally, these treatments are relatively more effective in
RRMS than in progressive MS. [17, 41]. Some DMTs are of broad action targeting the
peripheral immune system in general, such as interferon-beta (IFN-β) [41]. But many
other DMTs target specific components/ molecules involved in the immune response
cascade. Examples include natalizumab, a blocking monoclonal antibody that binds
the integrin VLA-4 on the surface of immune cells, so that VCAM-1/VLA-4
interaction does not take place. The inhibition of such interaction rapidly reduces
immune cell influx into the brain. Similarly, fingolimod and siponimod inhibit the exit
and subsequent migration of T lymphocytes from peripheral lymphoid tissues [58, 59].
Other monoclonal antibodies, such as anti-CD52 alemtuzumab and anti-CD20
rituximab, reduce the frequency or efficiency of inflammatory lymphocytes [17]. MS
patients also now have the option of chemotherapy and subsequent autologous
haemopoietic stem-cell transplantation. This treatment aims at eliminating
immunological memory responsible for damaging effects of autoimmune response.
This could occur through employing immune cells depleted transplant, so that the
chances of generating self-tolerant immune system are better [60].
1.7 Risk Factors for MS
What causes MS is not known, however it is widely accepted that there is an
interaction between genetics, epigenetics and environmental factors that render certain
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individuals more susceptible to MS than others [20, 61-64]. The difference in MS
distribution between individuals from different ethnicities living in the same region
(i.e. exposed to the same environmental factors) mirrors the influence of genes.
Whereas the accumulating evidence of increased MS risk in immigrants to high-risk
area compared to the general population in the country of origin denotes the impact of
the complex interaction between genes and environmental factors on MS risk [36].
1.7.1 Age
The pattern of MS occurrence has made MS a disease of the youth. The
incidence of MS peaks between the second and fourth decade of age, while pediatric
onset of MS [65] and MS starting in advanced age are relatively less common. This
makes age an important risk factor for MS [66].
1.7.2 Genetics
Susceptibility to MS is highest in Caucasians of northern European origin,
particularly in those originating from Scandinavia and Scotland, and lowest in
Chinese, Japanese, Samis, Uzbeks, Kazakhs, Gypsies, Eskimos, indigenous peoples of
the Americas, and Indigenous Australians [67]. To a modest degree, MS is heritable
among those who demonstrate increased genetic sharing. MS risk probability is about
1 in 40 when a parent or a sibling has MS. While there is 2-5% MS risk when one of
the same-sex fraternal twin has MS, if one of monozygotic twin has MS, the other twin
has 25-30% MS risk. Also, studies in half siblings and adoptees confirm the genetic
risk of MS (figure 1.8) [61].
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Figure 1.8: MS risk according to percentage of gentic sharing. Increased
concordance in monozygotic compared to dizygotic twins. When both parents are
affect by MS, their offsprings are at higher risk of developing MS than those with
only one affected parent. MS risk is almost 2 times less in half-siblings than in full
siblings. Adoptees who share no genetic background with the raising family face
almost the same MS risk that the general population do [20]
Multiple genes are found to impact susceptibility to MS. Repeatedly confirmed
reports point to the involvement of immune-associated HLA class II locus on
chromosome 6p21.3; linked to HLA-DR2 haplotype [64]. This locus is believed to be
accountable for 20-60% risk of developing MS [64]. For example, carrying
HLADRB1*1501 genotype together with

infectious mononucleosis (IM) history

increases MS risk to 7 folds, compared to less than 3-fold increase associated with
carrying HLADRB1*1501 alone [68]. Beside HLA class II region, HLA class I locus
has also been linked to MS risk. Susceptibility to developing MS and the risk of
acquiring IM seem to overlap in a region in HLA class I locus [68]. Furthermore,
several other non-HLA gene loci have been associated with MS risk, they appear to
carry small (odds ratios <2) effect on susceptibility to MS. Most of these gene loci are
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associated with regulating immune system response [61]. Some of the allelic variants
reported to be in association with increased MS risk seem to confer protective trait
against other autoimmune disorders indicating the complex link between
autoimmunity and autoimmune-related allelic variants [64, 69, 70].
1.7.3 Gender
As the case with numerous autoimmune disorders, MS occurrence has a
predilection for females. Female-to-male ratios of MS incidence has risen to reach 3:1
[66, 71-74]. This widespread consistency of biased female-to-male ratios suggests the
influence of sex hormones on susceptibility to MS. Thus, such demographic
distribution has necessitated stratification for gender in MS studies [75].
It has been suggested that the rising trend of decreased menarcheal age may be
one reason for increased female MS incidence. The interplay between age at menarche
and MS risk-related genotype may pave the way for early (adolescent) onset of MS
[76]. Also, the prevalence of HLA DRB1*1501 is found higher in female MS patients
than in their male counterparts [75].
1.7.4 Environmental factors
Epidemiological data indicate the involvement of environmental factors that
interact with genetic factors to shape immune response in developing MS [41, 77].
Immigration studies reveal changes (decrease or increase) in MS risk that has been
taking place within one-generation time. This is too little time for genes alone to cause
such changes [61]. Many environmental factors have been studied in association with
MS development [78].
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1.7.4.1 Sunlight and vitamin D
The involvement of ultraviolet (UV) light in determining MS risk came from
studies comparing duration of sun exposure in individuals who have developed MS
and in healthy controls, and the finding that UV-induced skin cancers are uncommon
in MS patients. On the molecular level, UV light shifts the immune reaction away from
Th1 cell response. But how much exposure to UV really contributes to protection from
MS is unclear given that MS prevalence is at the low side in MENA region, where
most people dress in conserved (skin-covering and UV-blocking) clothing. This
suggests that sun exposure on its own has little effect on MS risk. This factor rather
appears to interact with other genetic and environmental factors in ways to be
illustrated [79]. Effect of low sunlight exposure in increasing MS risk has been found
more pronounced in females than in age-matched males [80].
Within the same context, impact of serum levels of vitamin D on MS risk has
been studied extensively, alone and in association with other environmental factors
such as UV exposure and latitudinal effect [81]. It has been suggested that high serum
level of vitamin D is a protective factor against MS. Although debatable, vitamin D
supplementation has been linked to reduced MS symptoms. It is thought to happen due
to immunoregulatory functions served by vitamin D, including attenuating release of
inflammatory cytokines. Moreover, a link between polymorphisms taking place in
vitamin D receptor gene, vitamin D metabolism and MS risk has been considered [8284].
1.7.4.2 Obesity
Obesity is another risk factor reported in association with MS development. A
longitudinal study [85] conducted in US women has demonstrated that MS risk rises

23

to more than 2 folds in obese (body mass index ≥30 kg/m2) individuals. The effect of
obesity seems to influence susceptibility to MS mainly during adolescence [85].
Increased overall body fat is frequently accompanied by low levels of circulating
vitamin D, as this water-insoluble vitamin tends to get trapped within adipose tissue.
Thus, obesity may increase MS risk partly through causing a decline in levels of the
immune regulatory vitamin D [86]. Moreover, fat cells release inflammatory cytokines
providing a source of inflammation [85, 87]. Obesity is believed to interact with MS
risk-associated HLADRB1*1501 causing elevated probability of developing MS [87,
88]. Obesity may also interact with several other factors, including female sex,
adolescence age and black race, to increase susceptibility to MS [89].
1.7.4.3 Smoking
Smoking has been associated with increased MS risk in many studies [90-93].
It has been estimated that smoking contributes to 30-40% mean rise in MS risk. This
effect appears more pronounced in females than males [90]. Neurotoxicity, disrupted
immune regulation, general toxicity induced by chemical ingredients and byproducts
of tobacco [90] and triggering upper respiratory tract infections [92] are some of the
means postulated to explain effect of smoking on susceptibility to MS [90]. Although
smoking increases susceptibility to MS in both genetically- and non-geneticallysusceptible individuals, the magnitude of MS risk differs between the two groups.
Smokers positive for HLADRB1*1501 are shown to face a 14-fold rise in MS risk [94].
There are other environmental factors that lack consistency in their link to MS
risk including educational background and socioeconomic status, exposure to high
levels of stress [95], month of birth [96], geomagnetic instability (disrupted
magnetosphere that protects the earth from solar activity) [97], occupational hazard
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such as diary workers in the agricultural field [98], history of migraine [99], growing
up with siblings or going to a day-care center during early years of life, gut’s normal
flora [100] and having asthma [101]. Also because MS occurs spontaneously only in
humans and not in other non-human primates, some have argued for the association of
certain ‘human-specific’ elements in MS risk [102].
Overall, more than 40 environmental risk factors have been studied in
association with MS. Nonetheless, there is null association between the majority of
these factors and MS. According to Belbasis and co-authors’ umbrella review [103]
only three environmental factors appear strongly associated with MS, smoking,
Epstein Barr virus (EBV) and history of IM [103].
1.7.4.4 Infectious agents
Few incidents, such as MS outbreak in Faroe Island during World War II, and
few reports of MS incidence in clustering fashion (e.g. familial clustering of MS)
indicate the involvement of an infectious agent in establishing MS risk [61]. To explain
the involvement of infectious agents in the pathogenesis of MS, the hygiene hypothesis
has been introduced [104]. The hypothesis postulates that a number of unidentified
infections occurring during early years of life prevents development of MS later in
adulthood. Whereas exposure to these infections at advanced age in genetically
susceptible individuals predispose them to increased risk of developing MS [105]. The
hygiene hypothesis successfully answers certain aspects of MS geographical
distribution [106]. MS prevalence is low in tropical regions, where various bacterial,
viral and parasitic infections are endemic. This increases the chance of acquiring
infections as early as first year in life [107]. Similarly, MS risk is lower in individuals
who have been raised with siblings, therefore better chances of exposure to multiple
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microorganisms [108]. A stable rise in MS incidence has been observed in low-income
regions over the past 30 years [109]. Within the same period of time, these regions
witnessed a decline in frequency of infections as a result of advances in infection
control, better access to healthcare units and medical interventions (vaccines,
antibiotic, and enhanced sanitary conditions) [110]. The epidemiological linkage
between the two observed trends support the hygiene hypothesis [111]. However,
hygiene hypothesis falls short in explaining some epidemiological observations
including that the risk of developing MS in individuals who have never been exposed
to EBV is 10 fold lower relative to those who were exposed to asymptomatic earlylife EBV infection [108].
A wide range of infectious agents has been suggested to play a role in altering
MS risk, as either protective [112] or MS conferring factors, in genetically susceptible
individuals, when happening during specific life age [111]. For example, it has been
suggested that helminth infections may be protective against MS [113, 114]. Similarly,
clinical history of chickenpox (varicella zoster virus (VZV) infection) [115] and
cytomegalovirus (CMV) infection [116] are reported to reduce risk of adolescence
onset of MS. Moreover, it is believed that Helicobacter pylori infection exerts
immunomodulatory effects through antigens that can shift cell-mediated response
from the inflammatory Th1 subset to anti-inflammatory Th2 subset, thus decreases the
likelihood of developing autoimmune response associated with MS [117, 118]. On the
other hand, Mycobacterium Avium Subspecies Paratubercolosis (MAP) infection is
thought to promote MS risk in genetically predisposed populations such as Sardinians,
probably as a result of cross reactivity [119, 120]. Human herpesvirus 6 (HHV-6) has
also been suspected in association with MS risk, yet the link is debatable [121-124].
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Additionally, MS association with differential expression of human
endogenous retroviruses (HERVs) has been frequently reported [125-127].
Retroviruses are distinct in their capacity to make an intimate connection with host
DNA in a process called integration. In more precise terms, HERVs are retroviral
insertions into the human genome following infecting germ-line cells long time ago.
Since then, HERVs have been vertically transmitted from one generation to the next,
and now represent about 8% of our genome [128-131].
While the literature is rich with lists of infectious agents possibly associated
with MS [111, 122, 132-135], notably abundant evidence from sero-epidemiological
data and meta-analysis studies strongly highlight the role for EBV in MS pathogenesis.
In fact a recent umbrella review has reported that over 50% of meta-analyses
conducted on EBV association with MS had significant p values [103].
1.8 Epstein Barr Virus (EBV)
1.8.1 Herpesviridae
EBV is a member in the Herpesviridae [136], a large family that encompasses
over hundred identified DNA viruses [137]. Herpesviridae contains eight important
viruses, which infect only humans and belong to 3 subfamilies. Alphaherpesvirinae
covers herpes simplex virus type 1 and 2 (HSV-1 and -2), and varicella–zoster virus
(VZV), while Betaherpesvirinae includes human cytomegalovirus (CMV), human
herpesvirus 6 (HHV-6), and human herpesvirus 7 (HHV-7), and lastly,
Gammaherpesvirinae contains EBV and Kaposi's sarcoma herpesvirus (KSHV) [136,
137]. Characteristically, herpesviruses possess the capacity to persist in latent form
within particular tissues toward which these viruses show tropism. The latency persists
for the life of the host. Except for certain conditions, herpesviral particles and their
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gene expression is barely traceable under normal physiological settings. Yet, nucleic
acids of herpesviruses can be readily detected [137]. Overall, herpesviruses own a
characteristic structure consisting of four main components, DNA core encircled by
an icosahedral capsid, tegument, and lipid bilayer envelope [136, 137].
Herpesviruses DNA is unique in its sequence arrangement, and based on this
feature herpesviruses are categorized in A to F groups. Groups C to E contain the eight
human herpesviruses. The genome of group C herpesviruses contains a number of
well-characterized domains divided by several terminal repeats. EBV and KSHV
belong to group C. The genome of group D forms two equivalent molar sets as a result
of sequences from one terminal region being reiterated internally but in reverse
direction. VZV fits in group D. Lastly, the unique distribution of sequences within
genome of group E is arranged by internal reiteration of both terminal sequences in
opposite direction generating four equal molar sets. HSV and CMV are members of
group D [137].
Compared to other subfamilies, gammaherpesviruses are tropic toward limited
host range. In vitro, gammaherpesviruses replication takes place inside lymphoblastoid
cells, with a capacity to cause lytic infection in some cells. Latent infection is wellestablished in lymphoid tissues [137]. Gammaherpesviruses contain two genera,
Lymphocryptovirus (LCV; gamma 1) genus and Rhadinovirus (RDV; gamma 2) genus
[138].
1.8.2 Biology of EBV (human herpesvirus 4: HHV-4)
In 1964 Epstein’s laboratory was successful in detecting –using electron
microscopy- and isolating the first human oncogenic virus from Burkitt’s lymphoma
(BL) cell line, named EBV[139]. EBV is the archetype of the LCV genus [138]. EBV
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constitutes a fundamental part of human existence, because infected individuals are
persistently infected with EBV and more than 90 % of adults are EBV carriers [140].
Despite this high prevalence of EBV in the human population, occurrence of serious
EBV-related illnesses in most infected individuals is rare. Recent studies indicate that
EBV- associated cancers account for approximately 1.8% of all cancer-related
mortality worldwide [141]. This percentage, also, seems to be on the rise. Thus, the
overall EBV infection burden takes a toll on human population [141, 142].
Two types of EBV are known to infect humans, EBV-1 or –A and EBV-2 or –
B [143]. Geographically, EBV-1 is dominant in developed countries, while EBV-2 is
frequently circulating in Sub-Saharan Africa. The division of EBV into two types has
emerged based on genetic variation observed in the sequence of genes encoding EBV
nuclear antigens, namely EBNA-2, EBNA-3A, EBNA-3B, EBNA-3C and EBNAleader protein (EBNA-LP). Sequence variation between the two EBV types in primary
amino acids within EBNAs alleles ranges between 47% and 16% [138]. Furthermore,
each EBV type is sub-divided into strains, depending on variation in EBV DNA
repeats. Equal repeats in EBV DNA between EBV isolates from a population help sort
isolates into strains thus feasible tracking of EBV infection [138]. In vitro, EBV-1
shows better efficiency in immortalizing B lymphocytes than EBV-2. This is probably
due to sequence variations in EBNA-2. Also, lymphoblastoid cell lines (LCLs) have
better viability when infected with EBV-1 than with EBV-2 [144].
EBV possesses similar architecture of virus structure of that of other
herpesviruses. EBV capsid is made up of the following: major capsid protein (the
biggest among capsid proteins), minor capsid protein, minor capsid protein-binding
protein, small capsid protein, and portal protein. The protein tegument consists of viral
proteins including large tegument protein (BPLF1; the biggest among tegument
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proteins), large tegument protein-binding protein (BOLF1), major tegument protein
(BNRF1), myristylated protein (BBLF1), myristylated protein-binding protein
(BGLF2), palmitylated protein (BSRF1), capsid-associated protein (BVRF1),
packaging protein (BGLF1) and serine-threonine protein kinase (BGLF4). The cellular
proteins making up the tegument include actin, beta-tubulin, enolase, cofilin, and heat
shock proteins 70 and 90. The virus-encoded glycoproteins (gps) of the envelope
comprise gp350 (BLLF1), gp150 (BDLF3), gp78 (BILF2), gp42 (BZLF2), gB
(BALF4), gH (BXLF2), gM (BBRF3) and gN (BLRF1) [138].
1.8.3 Structure of EBV genome
A linear dsDNA molecule makes up EBV’s ~172 kb genome. EBV genome is
divided into short (US) and long (UL) largely unique regions, on which EBV genome
coding capacity heavily rely (figure 1.9). This division results from occurrence of 2-5
tandem, 0.5 kb direct repeats carrying the same sequence at both terminals (terminal
repeats; TRs) in addition to 6-12 tandem, 3 kb internal direct repeats (IRs). Open
reading frames (ORFs) of EBV genome carry much of perfect and imperfect tandem
repeats, IR2 and IR4. Close to the left end of UL region is IR2, which is homologous
to and mirrored in near to right end of UL with IR4. IR2 region covers several tandem
repeats of 125 bp which are rich in G-C content and greatly conserved sequences. Next
to these tandem repeats is 2 kb unique DNA. Similarly, IR4 contains high G-C content
tandem repeats of 102 bp followed by 1 kb unique DNA [145]. Both IR2 and IR4
contain the origins for initiation of replication of EBV DNA. Tandem perfect repeats
of EBV DNA are reiterated during DNA replication in varying frequency [138].
EBV DNA forms an episome during the event of EBV infecting a cell [146].
Each episome contains a characteristic number of TRs. This is determined by series of
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cleavage and assembly, and number of starting TRs within parent DNA. During EBV
latent infection, viral episome will contain a number of TRs identical to the parent’s
episome [147]. Thus, identical number of TRs within episomes in a population of
infected cells points to one common parent infected cell. Whereas variation in the
number of TRs indicates multiple cellular sources of infection. Other repeats in EBV
genome may also vary during viral replication, but they are less indicative of
heterogeneity due to either small size of the repeats or low frequency of reiteration
[147].

Figure 1.9: Structure of EBV linear DNA. (a) U1 is the short unique sequence and
U2 is the long unique sequence of EBV genome. U1 and U2 are divided by internal
repeats (IRs). Ori-P (grey-shaded circle): origin for EBV episome replication and
maintenance during latent infection. Ori-lyt (black-shaded circles located right to IR2
and IR4), origins for genome replication during lytic infection. Location of EBV
latent genes (on EcoRI and BamHI restriction linearized map) also shown [148]
ORFs in EBV genome are named after the BamHI-restriction fragment where
they are located [149]. Most of these ORFs are divided into latent (figure 1.10) and
lytic genes. Lytic genes include immediate early genes [150], early genes, and late
genes. Some of the lytic genes are translated into proteins that serve functions
analogous to certain human cellular proteins [144].
In vitro EBV infection of B lymphocytes leads to latent infection causing B
cells to be immortalized [151]. In these cells, up to 11 latent EBV genes are expressed.
Culturing peripheral blood lymphocytes isolated from EBV carriers under
immunosuppression (using cyclosporin A or depletion of T lymphocytes) leads to the
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outgrowth of EBV infected cells and the establishment of LCLs. Also, EBV isolated
from EBV positive cell lines can be used to directly infect resting B cells and produce
LCLs [152].

Figure 1.10: Position of latent genes on EBV episome [153]
In LCLs, several copies of EBV episome can be found in a single cell [153].
About 80 genes are encoded by EBV genome, but only a limited number has been
characterized and detected [138]. Latent proteins expressed in LCLs include six EBV
nuclear antigens EBNA-1, -2, -3A, -3B, -3C and –LP, and three integral latent
membrane proteins, LMP-1, -2A and -2B. Each one of the 6 EBNAs is encoded by
one distinct mRNA. Either Cp or Wp promoters (positioned in BamHI C and W region)
expresses a “rightward” key transcript that is more than 100 kb long. The differential
splicing of this transcript produces the different EBNA mRNAs. During early stages
of EBV infection of B cells, Cp promoter is transactivated by EBNA1 and EBNA2.
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Different promoters located in the BamHI N region express LMP transcripts. LMP
promoters are transactivated by EBNA2 [154].
The function of latent gene products appear to affect differentiation and
proliferation of host cells, providing EBV with the potential of cellular transformation
[155]. Most, but not all, of the latent genes are translated into functional protein
products. For example, EBV-encoded RNAs, EBER-1 and -2 are small nonpolyadenylated, non-coding RNAs expressed in high numbers (estimated at 107 copies
per infected cell) in all forms of latency [154]. This feature makes EBERs an ideal
target for the detection of EBV using in situ hybridization [156]. The viral genes
expressed in LCLs is a characteristic of latency III (all recognized EBV latent genes
are expressed). This form of latency has also been noted in some EBV-associated
conditions, such as post-transplant lymphoproliferative disorder (PTLD), EBVinfectious mononucleosis (IM), and AIDS-related lymphomas. In addition to type III
latency, 3 other patterns of EBV latent gene expression have been described [157]
(table 1.1). In the peripheral compartment of healthy immunocompetent EBV carriers
who have 1-50 infected B cells per 106 cells [158], the expression of almost all (except
EBERs [159] and probably LMP2A [160]) viral genes is silenced in non-dividing B
cells. This is defined as Latency program 0. In latency I program, represented by
Burkitt lymphoma, EBNA1 is the only viral gene expressed. In latency II program, the
two LMPs 1 and 2 plus EBNA1 are expressed, as seen in non-differentiated
nasopharyngeal carcinoma (NPC), EBV-associated Hodgkin lymphoma (HL) and T
cell lymphomas [155, 160, 161].
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LATENCY PROGRAM
LATENCY 0
LATENCY I
LATENCY II
LATENCY III

EBERS
+
+
+
+

EBNA1
+
+
+

LMP-1, -2
+
+

EBNA-2,-3,-LP
+

Table 1.1: EBV Gene expression profile. Different genes are expressed during
different latency programs [162]
1.8.4 Epidemiology of EBV infection
Herpesviruses are ubiquitous in human and non-human primates, and are
species specific [144]. Despite some recent attempts to deliberately establish EBV
infection in non-human primates [163], spontaneous EBV infection only occurs in
humans [164]. With almost universal EBV seropositivity, the virus in the majority of
the cases remains within the host without producing disease. Primary EBV infection
frequently takes place during early childhood (first 2-4 years) [165] or even during
infancy in some developing countries. Early EBV infection is widespread in
developing countries and does not usually present with clinical symptoms (figure 1.11)
[166, 167].

Figure 1.11: Age at EBV infection. Data represent 75% of the population in different
socioeconomic regions [164]. SE; South East
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However, primary EBV infection in developed countries tends to occur much
later, sometimes being delayed until adolescence or early adulthood. Such delayed
seroconversion is accompanied in 25%-70% of the cases with self-limiting
lymphoproliferative condition, referred to as infectious mononucleosis (IM) [165,
168].
Oropharyngeal secretion is the main source of EBV transmission. Close
contact with infected person’s saliva, where active shedding of EBV particles may
occur, leads to EBV horizontal transmission [169, 170]. Close contact between parents
and their infants may coincide with active shedding of the virus in the parent’s oral
cavity, increasing chances of acquiring EBV infection early in life [164]. Also, young
children may get infected through usual childhood acts of chewing toys that may be
contaminated or sharing utensils [153]. While the increased infection rate later in
adolescence and early adulthood is commonly due to kissing an EBV infected
individual who is shedding the virus [169]. All EBV infected persons shed EBV
virions in their saliva secretions at varying levels [138]. Accurate correlation between
the frequency of EBV shedding in saliva and peripheral viral load is poorly defined.
Thus, conditions promoting viral reactivation in the saliva may differ from that in the
peripheral blood [171]. EBV can be asymptomatically released in respiratory
secretions months post-infection and excretion can be intermittent during the life time
of the host [164, 169]. But so far exact periods of viral transmission are not known
[164].
EBV infection rate appears to adopt a bimodality in certain industrialized
populations, where increased rate of infection is seen during the first 4 years of life
and once again during mid-late adolescence (figure 1.12). Anti-EBV antibody titers

35

in EBV infected carriers are peaked during early childhood, likely reflecting primary
infection, and during late adulthood at which probable virus reactivation can occur
[172]. Decreased efficiency of the immune system in advanced age may contribute to
EBV reactivation [169].

Figure 1.12: Frequency of EBV seropositivity. Data represent four different
geographic populations [169]
EBV transmission can also occur via blood transfusion [173] and organ
transplantation settings [164, 174]. On an average estimate, a single unit of
erythrocytes has two EBV genomes, whereas 600-700 viral genomes can be carried
within a whole blood unit [175-177]. Blood transfusion in organ transplant recipients
carries the risk of developing PTLD [174]. Evidence for transmission of EBV through
transplacental route and sexual contact is limited [169].
Geographically, two EBV types, described earlier, are circulating in the human
population [178]. Moreover, genetic variation in EBV genome particularly in LMP-1
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gene is believed to be geographic area dependent. Polymorphisms in LMP-1 may
associate with incidence pattern of NPC particularly in isolates from endemic
populations [179, 180].
Similar to other childhood infections, the incidence of early EBV infection is
higher in populations with low socioeconomic status than in high socioeconomic
populations where delayed infection is primarily seen. Low socioeconomic status is
associated with congested living conditions, increased population density within a
given geographic area, poor hygienic standards and certain socio-cultural norms. In
these environments where the likelihood of early exposure to various infections is
increased, EBV seropositivity in young children is high [169].
Genetic and Gender-specific differences in EBV distribution are generally
absent. However, delayed primary EBV infection that is often associated with IM
symptomology is seen earlier and more frequently in females than in males [181].
Compared to their male counterparts, anti-EBV titers tend to be higher in females, who
are believed to mount stronger response from EBV-recognizing immune cells and
antibodies. Moreover, no genetic resistance to EBV infection has been reported, but
host genetics-dependent immune response to EBV may contribute to EBV-arising
diseases in some individuals but not in others [181].
1.8.5 EBV load in healthy carriers
EBV establishes a lifelong latent persistence in B lymphocytes, and latently
infected cells can be triggered to proliferate [164, 169, 170]. A transient increase in
peripheral EBV viral load occurs in primary infection, and thereafter declines to stable
levels that are below 100 copies per µg DNA [182, 183]. EBV resides in resting
memory B cells which express CD20 and CD27, and are phenotypically IgD- cells,
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that have undergone isotype-switch and somatic hypermutation [184]. Similar
frequency of EBV infected cells is seen in different body sites (blood, adenoids, and
tonsils), except for spleen and mesenteric lymph nodes where the level is 20 fold lesser
[185].
In African children residing in regions endemic for malaria, peripheral EBV
load is as high as that seen in IM patients [186]. EBV viral load differs between healthy
carriers, but within one person at a given point of time the load is more or less stable
[158, 187]. Nonetheless, healthy carriers experience raised viral loads at different
points of time indicating a transient viral reactivation that is soon tackled by a
competent immune system. The fluctuation of EBV levels can be determined in
PBMCs and plasma samples, with serum being the commonly preferred sample to use
for the consistency and reproducibility of measurements. Unlike NPC and PTLD
patients, EBV levels in plasma/serum can seldom be detected in healthy carriers, but
viremia can occur during viral reactivation periods [169].
In blood of healthy carriers, detection of transcripts for LMP2 and EBNA1 has
been seen, but generally peripheral EBV infected cells have latency 0 as described
earlier [188, 189]. In contrast to the blood, EBV infected cells in spleen and tonsil have
been reported to express latency program II [190]. In the tonsils, EBV infected cells
that may pass through the germinal center have been shown to express CD10. Within
tonsillar tissue, EBV infected cells can differentiate into plasma cells, and
transactivation of BZLF1 promoter triggers the beginning of viral productive (lytic)
cycle [151, 185].
Finally, equal EBV load and similar frequency of EBV latent antigens- specific
T lymphocytes have been reported in the blood and bone marrow. However, T
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lymphocytes reactive against EBV lytic genes appear 3 fold higher in the bone marrow
compared to that in the blood [138].
1.8.6 Dynamics of primary EBV infection
The oropharynx is the site where EBV infection starts, with viral gp350/220
binding to resting B cell surface CD21. While gp350/220 is EBV viral envelope
glycoprotein [191], CD21 or complement receptor 2 (CR2) is a receptor for C3d
complement molecule [192-194]. CD21 is expressed on B cells and possibly epithelial
cells of the tonsils [195-198]. This brief interaction between gp350/220 and CD21 is
followed by endocytosis. EBV lipid bilayer envelope fuses with B cell membrane with
the aid of EBV glycoproteins, gp42 which interacts with MHC class II molecules, gB
and gH/gL. EBV infecting epithelial cells has also been reported [199], with viral
BMRF2 interacting with epithelial surface integrins [138, 200, 201].
Next at the cellular level, replication and EBV shedding is initiated within the
oral cavity causing lysis of some infected squamous epithelial cells [202, 203] and B
lymphocytes. EBV then induces the expression of the full set of viral latent proteins in
infected B cells in the tonsils (latency III program). Through this growth-transforming
events, EBV infection spreads. Soon after that, competent cell-mediated immunity,
particularly anti-EBV CD8+ cytotoxic T lymphocytes (CTLs) [204, 205] and NK cells
of the innate system, is initiated. This immune response causes EBV to down-regulate
viral antigen expression [206], thus, growth-transforming program subsides.
Subsequently few infected cells make up infected memory B cell pool [207]. Lifelong
latent persistence is established in these memory B cells expressing latency 0
phenotype. These resting memory cells, as part of normal B cell life cycle, can travel
back and forth between peripheral circulation and oropharyngeal lymphoid tissues
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[208]. Occasionally, viral reactivation occurs in a portion of these cells [209], which
are successfully recognized and removed by EBV-specific CTLs. Also, few cells
sporadically enter the lytic cycle in the oropharynx. New viral particles are produced
and shed intermittently in saliva at low levels. Viral transmission, then, can occur and
the ‘life cycle’ of EBV continues in a new host (figure 1.13) [169, 210, 211].

Figure 1.13: EBV infection in an immunocompetent host. Comparison of events
occurring in EBV symptomatic and asymptomatic infection [210]
1.8.7 EBV and human diseases
Viremia, caused during EBV primary infection, triggers a response primarily
from NK cells and T lymphocytes (figure 1.14) [170]. Unlike IM, asymptomatic EBV
infection is believed to lack lymphocytosis and oligoclonality of antiviral CD8+ T
cells, in spite of initial viremia. In fact, the frequency of activated EBV-reactive CD8+
T cells reaches up to 18% of peripheral CD8+ T cell pool without marked increase in
the overall number of CD8+ T cells, compared to IM where CD8+ T cell population is
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expanded [212, 213]. An association between genetic variation in genes encoding
immune system components and development of serious EBV infection has been made
[210].

Figure 1.14: Anti-EBV immunity. Different gene products during EBV latent
infection and lytic replication (in differentiated plasma cells) are targeted mainly by
anti-viral CTLs and NK cells, respectively. Note that during early lytic cycle, MHCclass I- bound lytic antigens (BZLF1, BRLF1, BMRF1 and BMLF1) can efficiently
trigger a CD8+ T cells response. Whereas during late lytic cycle poor expression of
MHC class I molecules is compensated with increased expression of NKrecognizable NKG2D ligands (NKG2D-L). This phenotypic feature of infected cells
undergoing late lytic cycle makes them a target for NK cells [214]
EBV biology and latent persistence are heavily dependent on the virus-host
immunosurveillance equilibrium (figure 1.14) [160, 214]. Deficient immune
surveillance, such as in primary (congenital) immune deficiency, can disturb
(otherwise stable) EBV-host relationship. This is the case in X-linked
lymphoproliferative syndrome where immune functions, served by T lymphocytes and
NK cells, are impaired [215-217]. The importance of T lymphocytes in maintaining
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virus-host homeostasis is strongly supported by EBV- related lymphoproliferative
diseases in immunosuppressed PTLD and immunodeficient AIDS patients [153, 205,
218-221].
The role of EBV infection in cancer is well-documented. Annually, about
200,000 EBV-related malignant cases take place, and EBV now contributes to 1-2%
of cancer burden worldwide [210, 214]. Some of EBV tumors are preferentially
prevalent in certain ethnicities, occurring in immunocompetent individuals. The list of
such tumors includes NPC [222], BL [223], HL [224], and extranodal NK/T-cell
lymphoma of the nasal type [225]. The pathogenic role played by EBV as an
oncogenic virus in human malignancies has been studied extensively [226], and details
of EBV oncogenicity is beyond the scope of this thesis. Besides IM, EBV can cause
other diseases in immunocompetent hosts including IM-like chronic active EBV
infection [227], and probably autoimmunity [228-231].
Role of EBV in autoimmunity is debatable, and virus carriership is thought to
partly contribute to development of exaggerated immune response against selfantigens [232]. EBV has been linked to a number of autoimmune diseases such as
systemic lupus erythematosus and rheumatoid arthritis [232]. An accumulating body
of evidence suggests that EBV may also be involved in the pathogenesis of MS.
1.8.8 Available data for an association between MS and EBV
Data from epidemiological, serological, in vitro, and postmortem studies
support a role for EBV in MS pathogenesis. First evidence comes from identical
geographic distribution of IM (caused by EBV) and MS [233]. IM has also been
suggested as a strong risk factor for MS [234]. Reporting a history of IM increases the
relative risk of developing MS by 2.3 [235]. Thus, symptomatic EBV infection may
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be needed to direct the immune system toward an exaggerated response as seen in MS
[236]. Moreover, IM is believed to increase the risk of MS for 30 years post EBV
infection [237].
Another indicative observation of EBV contribution to MS is that almost all
MS patients are EBV seropositive compared to 90% of the global population [233].
This is consistent with the findings that the odds ratio of developing MS is higher in
EBV-seropositive persons than that in non-infected individuals (13.5 vs 0.06
respectively). However, the risk of MS rises in those EBV-seronegative individuals
soon after they seroconvert [232]. EBV seropositivity is also higher in pediatric MS
patients compared to their matched controls (83% vs 42% respectively) [238].
Comparing humoral response directed to EBV antigens, in the peripheral
and/or intrathecal compartment, between MS patients and their matched heathy
controls is another approach used to investigate potential relationship between the
virus and MS. Although no association between MS risk and EBV viral load exists,
MS risk is found linked to serum levels of anti-viral capsid antigen (VCA) and antiEBNA1 IgG antibodies [239]. Elevated antibody index directed against EBNA1
antigen in the blood tends to occur before the onset of MS [240], and thus these
antibodies may be a predictive marker for MS [241].
In relation to MS risk, there seems an overall triangle of links joining (a) history
of IM and anti-EBNA1 IgG titers, (b) history of IM and genotype of HLA DRB1*1501,
and (c) titers of EBV- specific antibodies and HLA DRB1*1501. It has been indicated
that both elevated titers of anti-EBNA1 antibodies and carrying HLA DRB1*1501
raises the risk of developing MS [233]. Whereas some believe that each of these two
factors operate independently towards MS risk [242], others suggest that circulating
anti-EBNA1 IgG interacts with genotype HLA DRB1*1501. This suggests similar
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pathways in which HLA molecules impact the risk of developing MS and immune
regulation of a lifelong EBV infection. In other words, elevated risk of MS is conferred
to individuals carrying increased load of anti-EBNA1 IgG and at the same time are
positive risk allele HLA DRB1*1501. The increased index of antibodies specific to
epitopes derived from EBNA1: 385–420 domain is particularly of great importance in
MS risk [243]. This domain carries sequences homologous to anti-inflammatory α-bcrystallin, to which amplified T cells respond in MS. Thus, it is possible that enriched
peripheral humoral response to specific EBNA1 domain breaks immune self-tolerance
and aggravates autoimmunity in MS [243]. Besides, phenotypic expression and levels
of EBNA1 has been associated with MS-related polymorphisms in HLA-DR and
HLA-DQ genes, proposing an overlap in regions linked to EBV infection and selfreactive immune response [62].
Furthermore, titers of EBNA1-specific IgG differ during different points of
time in disease course. Fluctuating titers of anti-EBNA1 are found to reflect alterations
in volumes of T2 MRI lesions [244]. Also, increased humoral response to EBNA1
could be a predictive marker for expanded disability status scale (EDSS) score [232],
and the start of definite MS clinical course, because CIS patients appear to have rising
levels of anti-EBNA1 antibodies just few years before the onset of definite disease
course [245-247]. Increased serum level of antibodies specific to ten peptides derived
from different regions of EBNA2 has also been reported in CIS patients. This may
suggest how early EBV needs to act to provoke humoral response to latent antigens
and promote MS pathogenesis [248].
EBV reactivation in the blood is reflected by increased load of IgM and IgA
antibodies specific for EBV early antigen (EBV EA) as well as evident presence of
EBV genome in the serum. These features were found by some to coincide with the
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occurrence of new MS episode but not during recovery periods, suggesting that EBV
reactivation may contribute to increased disease activity [249]. In fact, detecting
humoral response to EBV EA in the blood, thus peripheral EBV reactivation, has been
linked to increased MRI activity, manifested by the formation of additional gadolinium
enhancing lesions on MRI scans [232]. Others, however, could not find such
correlation [250].
Increased blood levels of soluble BAFF, a B cell survival factor that is involved
in regulating T cell immune response, and stable MS course are shown to be
concurrent. Whereas, increased humoral response to EBV antigens (particularly
EBNA1 and EBV lytic BOLF1 antigen) and MAP peptides have been found to occur
when blood levels of BAFF are low [251].
In a case-control study performed on Iranian IM patients, levels of vitamin D
during acute EBV infection were found to be markedly decreased in comparison to
control group [252]. Both IM and poor levels of vitamin D are associated with MS
risk. Thus, the two factors may interact in a pathway that eventually leads to
developing MS [252]. Consistent with these findings, another study conducted on
RRMS cohort, has revealed that low serum levels of vitamin D correlates with
increased humoral response to EBNA1 which seems more pronounced in persons
carrying HLA DRB1*1501 [81].
Atrophy in grey matter, measured on MRI scan, has been linked to the level of
antibodies directed to EBV VCA in MS patients but not in patients with other
neurological diseases and healthy controls [253]. Also, humoral response to both
EBNA1 and EBV VCA has demonstrated a significant correlation with volume loss in
brain cortex, the buildup of T1 black holes, and more white matter plaques in RRMS
patients [253].
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In addition to serology-based evidence, other case-control methodologies
depend on linking levels of peripheral or intrathecal cell-mediated response specific to
EBV and the risk of MS onset, and disease progression [254-258]. It has been reported
that the CSF of both MS and controls diagnosed with other inflammatory neurological
diseases (OIND) has heavily enriched immune response to EBV expressed proteins.
This intrathecal EBV-reactive immune enrichment has been reported to be greater in
MS patients than in OIND controls [259], and is translated into marked increase in the
expression of inflammatory IFN-γ and TNF-α [259]. The augmented response of EBVreactive T cells in MS CSF is accompanied by reduced response of EBV-reactive T
cells in the blood. This suggests that preferential expansion of CSF EBV-reactive T
cell population may be an intermediate route for T cells transmigrating to MS brain
[259]. Additionally, this response seems specific to EBV, because no expansion has
been seen in intrathecal CMV-specific T cell population in either MS or OIND
patients. Prolonged administration of daclizumab high-yield process (DAC HYP),
blockade monoclonal IgG1 for CD25 (IL-2R α subunit) expressed on T cells, has been
found to restore the number of EBV-reactive T cells in the blood and CSF of RRMS
patients back to uniform distribution [259]. Since intrathecal amplification of EBVreactive T cells has been found in MS and OIND patients, EBV may be a global
characteristic for neuroinflammatory conditions. Analysis of MHC class I-binding
pentamers has recently shown similar levels of CD8+T lymphocytes reactive to
‘HPVGEADYFEY’ epitope (derived from EBNA1 antigen) in MS and OIND patients
[260].
Lately, it has been demonstrated that different neuronal cell lines are infectable
by gammaherpesviruses EBV and KSHV using recombinant protein-tagged virus
[261]. The study showed that neuron cellular environment may be permissive for both
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latent and lytic cycle of EBV infection as manifested with the expression of EBNA1
and BZLF1, respectively. Therefore, these cell lines could serve as models for studying
potential pathologic events resulting from the presence of EBV in the CNS [261].
Although access to brain tissues, particularly fresh tissues, is not as easy as
collecting blood or CSF samples, a number of postmortem studies investigating EBV
association with MS continues to accumulate. In 2007, Serafini and co-investigators
looked at 34 blocks of autopsied cerebral tissues from 22 MS cases [262]. EBV has
been found in 21 MS cases and none in 11 control brain tissues. EBV has been
localized within CNS-infiltrating (CD20+) B cell and (CD138+) plasma cell
population, particularly the subsets making up lymphoid aggregates resembling
peripheral B cell follicles. EBV infected cells have been found to express a subset of
viral latent (LMP1, EBNA2) and lytic (BFRF1) antigens in acute MS. It has been
shown that EBV infected plasma cells are a target for perforin secreting CD8+ T cells.
These observations led the authors to conclude that EBV reactivation and disturbed
virus-host homeostasis may contribute to MS inflammation [263].
Another study performed on a limited number of autopsied brain tissues
reported MS tissue-specific expression of lytic BZLF1 in heavily infiltrated meninges,
where immune cells cluster forming B cell-like follicle structures, and within
perivascular infiltrates in active white matter lesions [264]. These lytically infected
cells, however, have not been found in other types of white matter lesions (chronic
active and inactive). Up to 10% of all BZLF1 positive cells have been found to
coexpress markers of Ig-positive plasma cells [264]. These results were replicated by
another study utilizing brain tissues from SPMS-diagnosed individuals [265]. The
expression of EBV lytic antigens (BZLF1 and BFRF1) has been shown in inflamed
perivascular regions within cortical parenchyma [265]. Again using a small number of
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postmortem cases, the physical presence of EBV has been demonstrated in active
white matter lesions with pronounced IFNα immunoreactivity within infiltrating
microglia and macrophages [266]. In contrast to these studies, other groups have not
found any evidence of EBV infection in the brain in MS cases [267-269].
1.9 Hypothesis and Objectives of the Study
While medical research’s purpose in MS has not changed -find the cause to
find a cure-, where to look and how to look should be cautiously considered not to end
up chasing a vague will-O’-the-wisp. The body of data implicating role of EBV in MS
pathogenesis is growing. In light of the above mentioned observations and
controversies, this project was aimed to address if EBV is a cofactor etiologically
involved in the pathogenesis of MS and how. Defining the precise frame relating EBV
to MS, if any, is highly important in establishing disease mechanism and risk
estimation, therefore help prevent MS or better treat MS patients.
In this study, we aimed to 1) determine if EBV is present in MS lesions using
a large sample size from MS and non-MS cases, 2) determine EBV viral load in MS
using quantitative PCR, 3) assess possible mode of entry of EBV to the brain, and 4)
determine EBV gene expression in MS.
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Chapter 2: Materials and Methods
2.1 Postmortem Brain Slices and Subjects Details
All experiments were carried out on autopsied human brain tissues procured
from Rocky Mountain Multiple Sclerosis Centre (RMMSC) tissue bank, University of
Colorado (Denver, CO, USA). Tissues were handled per established protocols of the
RMMSC brain tissue bank, and sliced into multiple coronal full hemispheric sections.
We received at least 1 coronal section, representing a specific anatomical region of the
human brain (figure 2.1), per postmortem case. All received slices were fixed and
stored in 10% buffered formalin.
A total of 135 brain slices representing 129 cases were stratified into 2 cohorts.
MS cohort included cases with clinical history of MS, and non-MS control cohort
included cases that never carried a definitive diagnosis of MS during their life time.
Whenever available, autopsy reports provided information about subjects’ age, sex,
cause of death, and gross pathology and histopathology of the brain. The clinical
course was indeterminate in 7 cases, thus they were excluded from data analysis. In
total 122 cases were studied; 101 MS cases and 21 non-MS controls.
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Figure 2.1: Coronal sections of human brain. The slices represent different
anatomical areas of the brain. Image retrieved from
http://www.mci.gr.jp/BrainBank/complete.jpg
2.1.1 Non-MS control cases
Control cohort was represented by 21 cases, 9 of which had a conspicuous brain
pathology at autopsy. They included Alzheimer's disease, progressive supranuclear
palsey-like tauopathy, meningioma and ischaemic brain injury. None of the 21 control
cases had any evidence of MS demyelinative plaques at autopsy, or MS clinical signs
during the life of the individual. Age of the controls at death ranged from 25 weeks of
gestation to 76 years. This cohort contained 15 males representing 71% of the non-MS
group. Demographics of non-MS control cases are summarized in table 2.1.
Control cases
Males
Females
Total cases

Number of cases
15
5
21

Age at death
51±27 (25 weeks of gestation-76) 55
51±11 (38-63) 52
51±24 (25 weeks of gestation-76) 55

Table 2.1: Demographics of non-MS control cases. Age at death, unless otherwise
stated, in years; expressed as mean± standard deviation, with data range in brackets
followed by the value of the group median
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2.1.2 MS cases
There were 101 cases in the MS cohort, predominantly consisting of females.
Mean age at death in the MS female group was 65±13 years old. One third of the cohort
was represented by males, with mean age at death 60±13 years old. Overall, cases in
this cohort suffered from MS for a duration of 7- 60 years before dying at ages ranging
between 29 and 98 years old. Clinical data of MS cases is summarized in table 2.2.
Detailed clinical data of both cohorts are in appendix I.
MS
Males
Females
Total

Number of cases
33
68
101

age at death
60±13 (42-98) 59
65±13 (29-92) 66
63±13 (29-98) 64

Age at MS onset
30±12 (28-51) 35
32±13 (16-53) 29
34+-12 (16-53) 32

MS duration
18±9 (10-30) 17
27±16 (7-60) 21
24+-15(7-60) 20

Table 2.2: Clinical characteristics of MS cases. Age at disease onset, age at death and
disease duration in years; expressed as means ± standard deviation, with data range
in brackets followed by the value of the group median
The severity of MS plaques was described in most of the cases as ranging from
‘moderately severe to severe burden’. This was consistent with the gross appearance
of some of the received coronal sections which showed few relatively depressed areas.
These areas were some-what tan-discoloured, shape defined, and difficult-to-cut.
Cerebral deep white matter, periventricular white matter, cerebellum, optic nerve and
chiasm, and brainstem were the most frequently reported areas to be affected by MS
demyelinative plaques. About 75% of the characterized cases were reported at autopsy
to be ‘chronic inactive’ MS. This was based on tissue lesions evaluated by histologic
(haematoxylin and eosin) and special stains (Luxol Fast Blue-Periodic Acid Schiff)
and immunohistochemistry (mainly for MBP and macrophage CD 68). A minimum
number of cases had myelin breakdown activity. Seven cases were reported to have
chronic active/reactivated MS.
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Nine cases were explicitly placed under progressive MS category, the majority
being secondary progressive multiple sclerosis (SPMS). According to autopsy reports,
spinal MS was identified in 7 cases, mainly affecting cervical region. In as many as
half of the examined cases, MS gross pathology included cerebral atrophy, thinning of
the corpus callosum, and enlargement of the ventricles and hydrocephalus ex vacuo.
Although meningeal fibrosis was identified in some cases, almost all cases were
described devoid of meningeal inflammation. Perivascular lymphocytic cuffing was
identified microscopically in 17 cases. Also, in few cases MS demyelinative plaques
coexisted with 1-2 different neuropathologies; specifically Parkinsonism, Alzheimer’s
disease, progressive multifocal leukoencephalopathy, immune reconstitution
inflammatory syndrome, atherosclerosis and arteriolosclerosis.
The brain tissues were preserved in formalin for a varying period of time,
ranging from 2 to 23 years (mean± standard deviation (SD) was 13±7 years). However,
the majority of the cases were preserved for a period that lasted for 5-16 years. The
mean time interval from death to fixation was 16 hours (postmortem interval ranged
from 4 to 41 hours). This study was approved by the local institutional ethics review
board, Al Ain Medical District Human Research Ethics Committee (application
number AAMD HREC 12/95).
The experiments carried out in this thesis, followed the criteria of an
observational case-control design. This design allowed us to easily compare inter- and
intra- group variables in situ (differences within the site of ailment) and draw
rationalized conclusions that open doors for new hypotheses about the involvement of
infectious agents such as EBV in an autoimmune disorder such as MS. However, one
must bear in mind that with this type of study design, certain biases can be introduced
such as the likelihood of imprecisely gathered patient data and missing information
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from retrospective records. The latter may interfere with outcome interpretation
particularly when common confounding factors, namely age, gender and ethnicity are
involved. Thus, a large number of samples was used to minimize the probability of
type II error.
2.2 Workflow of Processing Brain Coronal Slices
Each brain slice was handled in a sterile disposable petri dish. The required
areas were cut with a sterile scalpel. All tools including scalpel blade and forceps were
thoroughly sterilized to avoid cross-contamination between samples. From each case,
small pieces of tissues were cut in the following order:
1- Single small piece from white matter area was cut and placed into a sterile
disposable 15-ml centrifuge tube (product #430790, Corning). The tube was filled
with 1xPBS buffer for washing out the fixative and preparing for genomic DNA
extraction process.
2- Three more small pieces were cut from 3 different white matter regions (referred
to as white matter replicas), with the third one being cut from the grey matterwhite matter junction. White matter replicas were placed in tissue
processing/embedding cassettes and processed to paraffin blocks.
3- Maximum of 3 small pieces were cut from 3 different meningeal areas (referred
to as meningeal replicas), placed into a 1xPBS-filled 15 ml centrifuge tube and
processed for genomic DNA extraction.
4- Maximum of 3 small pieces were cut from 3 different meningeal areas, placed in
tissue processing cassettes and processed to paraffin blocks. An outline of the
study workflow is illustrated in figure 2.2.
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Figure 2.2: Workflow of experiments in the current study. WM: white matter, EBER-ISH: EBER in situ hybridization, IHC:
immunohistochemistry
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2.3 Extraction of DNA from Long-Term Formalin Preserved Brain Tissues
As mentioned above, the brain slices used in this study have been stored in
formalin for long time. It is an established fact that tissue fixation in formalin
introduces dramatic changes at the molecular level. Formaldehyde, a lab biohazard and
one of the most commonly used aldehyde fixatives, is a gas of small molecular weight.
This gas saturates into the aqueous state in the form of 37% formaldehyde solution. In
lab settings, 4% formaldehyde is used in a buffered solution. A buffered solution
serves as a pH stabilizer and is essential to avoid oxidization of formaldehyde and
buildup of formic acid, which decreases the pH of the fixative, and produces unwanted
effects in the fixed tissue [270].
Due to its efficient speed in both tissue penetration and fixation [270], formalin
is a good fixative for retaining tissue morphology and histological staining. It,
however, exerts profound limitations on the quality and quantity of nucleic acids that
can be extracted from such tissues. Formalin has been found to cause its fixative effect
through introducing cross-linking bonds between lysine residue and side chain of
various amino acids such as lysine, arginine, histidine and glutamine. Not only does
this cross-linking affect proteins, but can also directly or indirectly disturb nucleotides
organization and extend to the nearby histones [271].
Consequently, recovery of nucleic acids of good quality and quantity can
become challenging, if not impossible, as a result of time-dependent nucleic acid
degradation and sequence alteration [272]. This severe limitation of the usage of
formalin preserved archival tissues has forced scientists to come up with numerous
different ‘nucleic acid friendly’ fixatives that can substitute formalin [273], use fresh
frozen tissues [274] or establish optimized protocols [275] which maximize the
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recovery of genomic DNA. Therefore, in this work we optimized multiple factors in
the DNA extraction process in order to obtain the best possible quality of genomic
DNA. Using traditional phenol-chloroform biphasic extraction, the following steps
were initially followed before progressive amendments were introduced to tackle the
PCR inhibitory effects of extracted DNA:
1- Each piece of brain tissue (~250 mg) was cut and placed in a 15 ml tube filled
with 1xPBS (pH 7.4).
2- Formalin, the fixative solution, was washed out by washing the tissue in 2 changes
of 1xPBS buffer (1xPBS: 137mM NaCl, 2.7mM KCl, 4.3mM Na2HPO4, 1.4mM
KH2PO4).
3- In the final 1xPBS wash, the tissue was homogenized using the homogenizer
(ULTRA-TURRAX, T-25), for ~2 minutes or until the tissue was uniformly
homogenized. Meninges were macerated with a pestle on a sterile petri dish rather
than with the homogenizer. Using the latter would increase the possibility of
cross-contamination between samples.
4- The homogenate was spun down at room temperature at 4000 rpm for 5 minutes,
(Allegra X-15R centrifuge, Beckman Coulter, USA).
5- The washing buffer (1xPBS) was discarded, and 2 ml of sodium dodecyl sulfate
(SDS)/ proteinase K-based digestion buffer (TENS buffer) was added. This buffer
consisted of 10mM Tris, pH 7.5, 400mM NaCl, 100mM EDTA, 1% SDS and 0.5
mg/ml proteinase K (Cat No. P6556, Sigma).
6- Tissue homogenate was mixed well with the digestion buffer by continuously
inverting the tube. The tube was then incubated for 3 days at 55 °C in a shaking
water bath.
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7- At the end of the incubation period, proteinase K enzymatic reaction was stopped
by spinning down the lysate at room temperature for 15 minutes at 4000 rpm.
8- Supernatant was pipetted off and transferred to a new sterile centrifuge tube.
9- For genomic DNA extraction, phenol–chloroform–isoamyl alcohol (25:24:1,
Sigma, USA) was then added (under a fume hood due to its toxicity) to the lysate
in 1:1 volume ratio and mixed thoroughly (by continuously inverting the tube).
10- The mixture was then spun down at 4000 rpm for 15 minutes at room temperature,
to separate the 2 phases (lower organic and upper aqueous phases) with an inbetween fuzzy rim that is kept minimal by chloroform.
11- The supernatant was pipetted off with caution to avoid contamination with the
interphase which could reduce the purity of the recovered DNA. This aqueous
supernatant was transferred to a new sterile centrifuge tube.
12- Phenol-chloroform extraction step was repeated once more to ensure extraction of
pure and protein-free DNA.
13- DNA was precipitated by adding 1/10th the volume 3M sodium acetate and cold
absolute ethanol (AppliChem, 131086) in 1:1 volume ratio.
14- The mixture was incubated at -20˚C overnight or at -80˚C for 3-4 hours.
15- The mixture was spun down using a bench centrifuge at maximum rpm for 30
minutes. Salted ethanol was discarded.
16- Cold 70% ethanol was added to wash precipitated DNA. The mixture was spun
down at maximum rpm for 5 minutes and supernatant was discarded.
17- The pellet was air-dried, subsequently ~50 µl nuclease-free water or TE buffer
(10mM Tris, pH 8.0, 1mM EDTA) was added to dissolve extracted DNA.
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18- DNA amount and purity were estimated using NanoDrop-1000 instrument
(Nanodrop Technologies, USA) by measuring the absorbance at 260 and 280 nm
(A260/A280 ratio).
These steps were performed taking all possible precautions to avoid DNA
contamination. Also, genomic DNA from an EBV-positive control, B95-8 cell line,
was extracted following these steps. The outcome of this protocol was then compared
with that of:
1- Commercial DNA extraction kits. (QIAGEN (QIAamp DNA Mini Kit) and
Promega (Wizard® Genomic DNA Purification Kit))
2- DNA extracted from paraffinized and deparaffinized tissues. The rationale
behind this was that tissue processing pre-paraffin embedding and post-dewaxing
could potentially eliminate tissue fixative and other PCR inhibitory components:
a- Small pieces of tissue were cut, placed in a histology cassette, then processed
(see tissue processing section 2.7) and embedded in paraffin wax.
b- The paraffin block was sectioned using the microtome at thickness of 10 µm.
Three 10 µm sections were collected in 1.5 µl-Eppendorf tubes.
c- To deparaffinize the tissue, 500 µl xylene (Sigma, 16446) was added (under
fume hood) and incubated at room temperature for 15 minutes.
d- Tubes were spun down at 13000 rpm for 10 minutes. The supernatant (wax
dissolved in xylene) was discarded.
e- To completely eliminate xylene, 500 µl absolute ethanol was added and
incubated at room temperature for 15 minutes, and step ‘d’ was repeated.
f- Finally, tissues were treated with SDS/PK-based digestion buffer and
incubated at 55˚C for 24 hours. Subsequently, phenol-chloroform extraction
was continued as described above.
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3- Changing/ optimizing content of digestion buffer.
In a separate experiment, the above defined TENS digestion buffer was substituted
with a buffer containing 500mM TRIS, pH 9.0, 20mM EDTA, 10mM NaCl, 0.1%
SDS and 0.5 mg/ml proteinase K (referred to as optimized digestion buffer),
keeping all other steps constant.
4- Changing/ optimizing protein digestion (I): optimizing proteinase K
concentration.
In a separate setup, 4 weight-equal tissues were incubated with the optimized
digestion buffer for only 24 hours. Each tissue (represented with 5 replicas) was
treated with 5 different final concentrations of proteinase K; 2.5, 1.25, 0.62, 0.31
and 0.15 mg/ml simultaneously. DNA quality, quantity and amplifiabilty were
checked to determine the best proteinase K concentration required for DNA
extraction.
5- Changing/ optimizing protein digestion (II): optimizing the length of
incubation with proteinase K.
In a separate experiment, 26 tissues were incubated with the optimized digestion
buffer. After 39 hours of incubation the reaction was stopped for 8 samples, and
the rest of samples continued incubation. After 68 hours from the start of
incubation the reaction was stopped for another 10 samples. The remaining 8
samples were incubated for a total 116 hours in the digestion buffer. DNA quality,
quantity and amplifiabilty were checked to determine the best length of
incubation.
6- Other minor changes: extensive washes, DNA salted precipitation, and
adjusted Mg2+ concentration during PCR master mix preparation.
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a- As a way of eliminating formalin from the tissues, tissue homogenates were
washed with 6-10 changes of 1xPBS. In each wash, tubes were continuously
inverted on the tube rocker to ensure thorough wash.
b- In DNA precipitation step, adding 1/10th the volume 3M sodium acetate was
substituted with adding 1/5th the volume 0.1M sodium chloride.
c- Three different concentrations of MgCl2 were tested; 2mM, 3mM and 4mM.
Quality control parameters were then checked including:
1- Quantity (amount of DNA extracted as determined by NanoDrop-1000
spectrophotometer).
2- Purity (good 260/280 ratio).
3- Quality (extent of DNA fragmentation) determined by sizes of DNA
fragments by gel electrophoresis of 5 μl of the extracted DNA using 1.5%
agarose gel stained with ethidium bromide in 0.5x TBE (0.9M Trisma Base,
0.9M Boric Acid, and 0.5M EDTA, pH 8.0) buffer.
4- Amplifiability (overcoming inherent PCR inhibition and obtaining PCR
amplicons). Once all parameters were optimized for the recovery of
genomic DNA of good quality and quantity for the downstream molecular
work, genomic DNA was extracted from all 122 cases. DNA was extracted
from a single white matter area from each case, and from 3 different
meningeal areas. Due to the increased fragility of the meninges, particularly
with the harsh conditions found in formalin fixation for years, it was not
always possible to obtain 3 replicas of meninges. Thus, some cases were
represented by only 1 or 2 replicas.
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2.4 Standard PCR: PCR Amplification of EBV BamHI W Fragment
Concentrated DNA was diluted to roughly 50 ng/µl per aliquot. For PCR
internal control, 3 house-keeping genes were used to check for the suitability of the
extracted DNA for PCR amplification: (a) β-globin (amplicon size 104 bp) (GenBank
ref.: NM_000518.4) [275], (b) GAPDH (amplicon size 351 bp) [276], and (c) GAPDH
(amplicon size 560 bp) (GenBank ref.: M33197) [277]. Primer sequence is listed in
table 2.3.
PCR reaction was carried out in a 30 μl final volume. The reaction was
composed of 1× PCR buffer, 10pmol of forward and reverse β-globin primers, 1× Q
solution (QIAgen), 0.05mM of deoxynucleotides, 1 unit of Taq DNA polymerase
(QIAgen), and 100 ng of genomic DNA. Genomic DNA extracted from B95.8 was
used as positive control, while at least 2 negative controls consisting of nuclease-free
water (or no DNA template) were used to monitor PCR contamination. Applied
Biosystems thermal cycler PCR System 2700 was used with the following thermal
cycling conditions: initial denaturation step at 94°C for 5 minutes, 40 cycles of brief
94°C denaturation (1 minute), annealing temperature for β-globin at 55°C (45 seconds)
and elongation at 72°C (30 seconds). PCR was concluded with a final extension of the
full PCR product at 72°C (5 minutes). Amplicons were electrophoresed in 2% agarose
gel stained with ethidium bromide.
Once PCR internal control was confirmed, amplification of relatively small
EBV-specific primers flanking portion of EBV Bam H1W internal repeat sequence
was performed. PCR for EBV BamHI W 152 bp-fragment (table 2.3) [163] was carried
out following the same PCR reaction ingredients as with the house-keeping genes. The
annealing temperature for EBV primers was 60°C.
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2.5 PCR Amplification of Three Common Human Herpesviruses
Sixteen white matter DNA samples, positive for EBV, were randomly selected
and screened for the presence of other ubiquitous herpesviruses. PCR primers for 3
viral genomes (reside latently in a large percentage of human population) were selected
to flank short sequences that would allow DNA of average integrity to be successfully
amplified. The first pair of primers were used to amplify a conserved 92 bp sequence
within DNA polymerase gene-coding region from herpes simplex virus-I (HSV-1)
[278]. The second pair of 20-mer primers flanked 139 bp sequence in cytomegalovirus
(CMV) genome [279], and the last pair was chosen to amplify a target sequence of 137
bp within human herpes virus type 6 (HHV-6) genome (table 2.3) [279]. PCR thermal
conditions were kept constant for all primers; with 40 cycles of amplification. The
annealing temperatures for HSV, CMV and HHV-6 primers were 63˚C, 62˚C, and
53˚C respectively.
Genomic fragment
β-globin
GAPDH
GAPDH
EBV
HSV-1
CMV
HHV-6

Primers sequence
F: 5' GAG GTT CTT TGA GTC CTT TGG 3'
R: 5' CAT CAC TAA AGG CAC CGA GCA 3'
F: 5' GCC TCC TGC ACC ACC AAC TG 3'
R: 5' CGA CGC CTG CTT CAC CAC CTT CT 3'
F: 5' CAT GTT TGT GAT GGG TGT GAA CCA 3'
R: 5' GTT GCT GTA GCC GTA TTC ATT GTC 3'
F: 5' CAC TTT AGA GCT CTG GAG GA 3'
R: 5' TAA AGA TAG CAG CAG CGC AG 3'
F: 5' CAT CAC CGA CCC GGA GAG GGA C 3'
R: 5' GGG CCA GGC GCT TGT TGG TGT A 3'
F: 5' CCG CAA CCT GGT GCC CAT GG 3'
R: 5' CGT TTG GGT TGC GCA GCG GG 3'
F: 5' TTA AAC AGC CGT TGT CAG GG 3'
R: 5' GTA TCC CGA CGG CAG AGG TT 3'

Product size (bp)
104
351
560
152
92
139
137

Table 2.3 Sequence of PCR primers. Primers were used in amplifying genomic DNA
extracted from brain tissues
2.6 Quantitative Real-Tme PCR
To determine EBV viral load in the brain, quantitative real-time PCR (qPCR)
was performed on EBV BamHI W-PCR positive DNA samples from the white matter
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and meninges. This method for quantifying EBV DNA has been previously described
[163] and was applied to all EBV positive white matter DNA, and to EBV positive
meningeal DNA that were positive for EBV in at least 2 replicas by standard PCR.
EBV positive replicas from the same case were pooled into one 50 ng/µl aliquot.
The very first step in qPCR was establishing a standard calibration curve of
EBV- positive control DNA, from which viral copy numbers in test samples could be
extrapolated. To establish a standard curve we used Namalwa cell line (CRL-1432,
American Type Culture Collection), an EBV positive Burkitt's lymphoma cell line in
which 2 integrated copies of EBV genome reside within each cell. Ten-fold serial
dilutions of Namalwa DNA (100, 10, 1, 0.1, and 0.01 ng/µl) were prepared, run in
duplicates and quantified by qPCR. Then, generated mean value of cycle threshold
(Ct) of duplicate wells for each dilution was taken, and plotted against the logarithm
of DNA amounts of the serial dilution of Namalwa genomic DNA. Establishing a good
standard curve was ensured through observing good correlation coefficient. White
matter and pooled meningeal DNA were also run in duplicates and Ct mean values
were generated by qPCR. BamH1W assay was most sensitive, presumably because it
targets a reiterated sequence that is present at approximately 10 copies per EBV
genome [280].
Quantitative PCR reaction was set up in dark laminar flow hood using
MicroAmp® Optical 96-well Plates (Applied Biosystems). The work area was cleaned
with 70% ethanol and UV-irradiated for 15 minutes prior to setting up the reaction.
Also to reduce potential contamination, a separate set of sterile pipettes designated for
PCR work were used. To monitor contamination, nuclease-free water was included in
at least 4 wells as negative control. Also, it was essential to minimise pipetting error
that could affect the accuracy of PCR results, therefore reaction solutions were mixed
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well and pipetted cautiously. Each reaction took place in a final volume of 20μl,
containing 1x TaqMan Universal PCR Master Mix, 1x primer-probe mixture, 50ng of
DNA template, and 8 μl DNase-free water.
Once individual reactions were set up, the plate was covered with an optical
strip (adhesive cover) and spun down at 3000 rpm for 2 minutes before placing it into
Applied Biosystems 7500 real-time PCR machine (Applied Biosystems, Germany).
BamHI W primer-probe combinations (forward: 5`GCA GCC GCC CAG TCT CT3`,
reverse: 5`ACA GAC AGT GCA CAG GAG CCT-3`, and probe: 5`(6FAM) AAA
AGC TGG CGC CCT TGC CTG (TAMRA)-3`) were custom-designed according to
published sequences [280] and acquired from Applied Biosystems. The probe was
labeled with FAM, a fluorescent tag emitting a spectrum upon excitation by prism at
488 nm. EBV BamHI W amplification conditions were as follows: 5 minutes at 95°C,
and then 40 cycles of denaturation at 95° C for 15 seconds, annealing at 60°C for 1
minute and extension at 72°C.
2.7 Processing of Formalin Preserved Tissues
Formalin fixed brain tissues were processed in a fume hood because of the
well-documented toxicity of formalin. Small pieces of tissues were cut out from each
coronal slice on a formalin-filled sterile petri dish using a sterile disposable blade to
avoid carryover contaminants between cases. Tissues with a mean thickness of 3 mm
and mean dimensions 1.5x1 cm were cut from brain parenchyma (white matter and
white matter-grey matter junction) and meninges as mentioned earlier (figure 2.2).
Tissues were placed on a filter paper and transferred into pre-labelled histology
cassettes. All cassettes were collected in formalin-filled jar ready for processing. The
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orientation of the tissue was maintained in such a manner that the surface of the tissue
that was intended to be sectioned first faced the bottom of the cassette.
1- First, formalin was discarded, and cassettes were incubated in series of graded
ethanol, 30%, 50%, 70%, and 90% (each for 45 minutes). Cassettes were then
incubated in 2 changes of absolute ethanol (each for 1 hour) to eliminate all water
from the tissues.
2- Tissues were cleared with xylene, by incubating cassettes in ethanol-xylene
mixture (1:1 volume ratio) for 45 minutes, and after that in 2 changes of absolute
xylene for 30 minutes each.
3- For paraffin impregnation, cassettes were incubated in 3 changes of molten
paraffin wax (Histoplast PE, Thermo Scientific, Ref. No. 8330) in 60˚C oven, each
for 30 minutes.
4- Tissues were then embedded into wax blocks using moulds of appropriate size.
Finally, blocks were trimmed to remove excess wax from all sides so it could fit
perfectly in microtome block holder.
5- Microtomy: cold paraffin blocks were levelled using rotary microtome at 10-15
µm thickness to get rid of excess wax on block surface. Tissues were then
sectioned at 5µm thickness. The produced ‘ribbons’ were floated on a 40˚C water
bath, and collected using silanized (coated) slides. Coating slides (appendix III)
with 3-aminpropyltriethoxysilane (Sigma, A3648) prior to using them is essential
for tissues to stay adherent to slides and eliminate detachment.
6- Slides were dried on warm plate, ready to be stained. A summary of tissue
processing demonstrated in figure 2.3.
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Figure 2.3: Tissue processing workflow. Processing started with cutting out the target
area from brain coronal slice, to undergo series of dehydration, clearing and wax
impregnation before reaching embedding facility; where it was blocked out in
moulds, and subsequently trimmed to go through microtomy. Finally, sections were
collected in a warm water bath using coated slides and dried overnight
2.8 Localization of EBV Infected Cells Using EBER In Situ Hybridization
In situ hybridization (ISH) for EBV encoded RNAs (EBERs) was performed
as previously described in detail [156]. Briefly, two oligonucleotide probes were
custom-designed for the detection of EBERs. Anti-EBER1 is an antisense probe
consisting of 30-nucleotides complementary to a sequence stretching from position 91
to 120 on EBER1. Anti-EBER2 is the second antisense probe consisting of a 30-mer
sequence complementary to nucleotides stretching from 82 to 111 nucleotides on
EBER2 (figure 2.4).
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Figure 2.4: EBERs structural prediction. Anti-EBER1 and Anti-EBER2
oligonucleotide probes bind to the blue highlighted sequence on EBER1 and the pink
highlighted sequence on EBER2, respectively [281]
Each one of the 2 antisense probes was end-labelled individually with
Digoxigenin molecule (DIG) using commercially available end-labelling kit (Cat #
03353583910, Roche) (figure 2.5) as follows:
a- 4 µl 5x tailing buffer: 1M potassium cocodylate, 125mM Tris-HCl, 1.25 mg/ml
bovine serum albumin, pH 6.6,
b- 4 µl CoCl2 solution (25mM),
c- 1 µl Dig-dUTP (1mM Dig-11-dUTP in ddH2O),
d- 1 µl dATP (10mM in ddH2O),
e- 1 µl terminal transferase (400 U/µl),
f- 1 µl probe (1 µg/µl), and
g- 8 µl ddH2O was added to make up the reaction volume to 20 µl.
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Figure 2.5: End labelling probes with DIG. The reaction is catalysed by terminal
transferase. Image retrieved from https://lifescience.roche.com/shop/products/diglabeling-methods
After mixing the tubes well, they were incubated in 37°C heat block for 30
minutes. The reaction was stopped by adding 2 µl of 0.2M EDTA (pH 8.0). At this
stage no purification was needed, because the nucleotides that were not incorporated
would be washed off during the stringency wash, a critical step during EBER-ISH.
Finally, the volume of the labelled probe was made up to 100 µl by adding 78 µl of
sterile TE buffer (50mM Tris-HCl, 1mM EDTA, pH 7.6). Thus, the concentration of
the labelled probe was 10 µg/ml. Then, the 2 labelled probes were mixed together. To
create negative control probes, sense probes of non-complementary sequence to the
same segments of EBER1 and EBER2 were labelled with DIG in a similar reaction to
that described above. The two sense probes were mixed together (final concentration:
10 µg/ml). Once the probes were labelled, EBER-ISH was carried out as following:
1- Slides were warmed in a 60°C oven for an hour to melt the wax, and sections were
deparaffinised in 2 washes of xylene, each for 10 minutes. Sections were then
dehydrated in graded ethanol (70%, 90% and 100%), each for 5 minutes.
2- The activity of endogenous tissue peroxidase was quenched using 0.5% H2O2
(30% w/v, Panreac, 121076) in methanol (Panreac, 131091) for 20 minutes.
Sections were then dehydrated in absolute ethanol for 2 minutes, and air dried.
3- In a 37°C humid incubator, sections were incubated with a 150-200 µl volume of
proteinase K solution (10 mg/ml proteinase K diluted 1:100 in TE buffer, final
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concentration 100 µg/ml) for 10 minutes. The reaction was stopped by washing
slides in water, and slides were dehydrated in absolute ethanol.
4- Then, slides were incubated with 25 µl volume of hybridization solution,
consisting of 10 µg/ml labelled probes diluted 1:50 (final working concentration
0.2 µg/ml) in hybridisation buffer (50% formamide, 5% dextran sulphate, 2x SSC)
(appendix II). Coverslips of a dimension 32x22 cm were used to cover the tissue.
The coverslips helped spread the hybridization solution over the entire tissue, and
eliminate evaporation. Then, slides were placed in a hybridization chamber
humidified using wet filter paper (in 2xSSC).
5- Labelled probes and target EBERs were denatured in a domestic microwave for 7
minutes at the lowest power. Subsequently, overnight hybridization was carried
out in a 42°C oven.
6- On the following day, coverslips were removed and sections were washed in 2
changes of 2xSSC, each for 10 minutes.
7- After that, stringency wash was done to get rid of unbound probe and eliminate
non-specificity. Slides were incubated in 2 changes of pre-warmed 0.1xSSC at
50°C, each for 10 minutes.
8- Slides then were washed in 2 changes of 2xSSC, followed by a wash in 1xPBS,
each for 5 minutes.
9- Sections were incubated for 30 minutes at room temperature in a humidified tray
with the primary antibody. For this, a solution of 150-200 µl was added per
section. Monoclonal mouse anti-DIG antibody (clone D1-22, Sigma Cat# D8156)
was diluted at 1:2500 in 1x PBS containing horse serum diluted at 1:100 provided
in the Ultra-sensitive ABC peroxidase mouse IgG staining kit (Thermo Scientific,
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Cat# 32052). Unbound primary antibody was then washed off in 3 changes of
1xPBS, each for 10 minutes.
10- Sections were incubated for 30 minutes with 150-200 µl of biotinylated antimouse secondary antibody (Thermo Scientific, Cat# 32052) diluted 1:200 in
1xPBS containing 1:100 diluted horse serum. Sections were washed in 3 changes
of 1xPBS, each for 10 minutes.
11- The ABC solution (Thermo Scientific, Cat# 32052) was prepared 30 minutes prior
to its use to stabilize, by diluting each of reagent A (avidin) and reagent B
(biotinylated peroxidase) 1:50 in 1xPBS. Tissues were incubated with 150-200 µl
of ABC solution for 30 minutes in a humidified tray. Sections were washes in
1xPBS.
12- The color of the reaction was developed by adding 1ml of 25 mg/ml 3, 3′diaminobenzidine (DAB) (Sigma Cat# D5637) to 100ml 1xPBS containing 0.02%
hydrogen peroxide (final concentration of DAB 250 µg/ml). Slides were incubated
in DAB solution for 20 minutes. A control slide would be checked under the
microscope after 20 minutes to ensure brown color development. If the color was
thought to be underdeveloped, slides would continue incubation with DAB for
maximum of 10 minutes more.
13- Slides were rinsed in tap water, and then briefly counterstained with freshly
filtered Harris hematoxylin (Shandon Instant Hematoxylin, Thermo Scientific,
Cat. #6765015) for 2 minutes. Subsequently, slides were rinsed in water,
decolorized for ~1 minute in acid alcohol (1% HCl in 70% ethanol), and blued in
running tap water for 10 minutes.
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14- Slides were then dehydrated in absolute ethanol followed by thorough air dry,
cleared in xylene, coverslipped using xylene based DPX mounting medium
(Sigma, Cat # 06522), and observed under a light microscope (Olympus BX51).
Assessment criteria: based on number of positive cells per section, cases were
divided into ‘+’ for 1- 49 EBV positive cells, ‘++’ for 50-200 EBV positive cells, and
‘+++’ for >200 EBV positive cells; i.e. heavily infected. For histopathology remarks
such as inflammatory cell infiltration, hematoxylin and eosin (H&E) staining was also
performed.
2.8.1 Quality control for EBER-ISH
Multiple controls were included for EBER-ISH to ensure correct staining
procedure. First, both MS and non-MS cases were processed and stained under
identical conditions. Second, a pretested positive control tissue was included in each
batch. Positive control paraffinized tissue was either tonsil tissue from a patient
diagnosed with EBV positive infectious mononucleosis or B95-8 cell line (an EBV
positive marmoset cell line). Third, to verify specificity, negative control probes were
included. For each tissue, one section was hybridized with labeled EBER antisense
probes, and one section with EBER sense probes in parallel.
Cases which were found to be EBER-ISH positive, were further confirmed by
treating the tissues with RNase A prior to incubation with antisense probe. The signal
should be removed after RNase treatment if the binding was specific to RNA in the
tissue and not to another cellular target. For RNase treatment:
1- Tissues were processed according to the above described EBER-ISH protocol.
Once tissues were digested with proteinase K and subsequently dehydrated, they
were incubated in humidified incubator at 37˚C with Ribonuclease I (RNase A)
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(Sigma, R5125) for 30 minutes. About 200 µl of 10 mg/ml RNase A diluted at
1:50 in 2xSSC (final concentration 0.2 µg/ml) was added and spread evenly on
each section.
2- Tissue RNA digestion was stopped by washing slides in water. Slides were then
dehydrated in absolute ethanol.
3- Slides were incubated with EBER antisense probe and the EBER-ISH procedure
performed as described above.
2.9 Hematoxylin and Eosin Stain for Paraffinized Brain Sections
1- Tissue sections were deparaffinized in xylene as described above, then hydrated
in serial ethanol dilution (100%, 95%, 90% , 70% and 50%), each for 3 minutes,
before bringing slides into water for 5 minutes, preparing them for the aqueous
stain.
2- Brain tissues were stained with freshly filtered Harris hematoxylin for 3 different
periods of time; 5, 10 and 15 minutes. Brain tissues required long time to uptake
the right crispness of hematoxylin stain, so sections were incubated in
hematoxylin for 15 minutes.
3- Slides were rinsed in water to remove excess hematoxylin and differentiated in
1% HCl in 70% ethanol for one minute. Slides were then blued in running tap
water for 10 minutes.
4- Slides were rinsed in 95% ethanol for one minute and stained with Eosin Y (eosin
in alcoholic solution, RAL diagnostics, UN1987) for 30 seconds. For
differentiation, tissues were rinsed in 95% ethanol for 30- 60 seconds.
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5- Slides were washed and dehydrated in 3 changes of absolute ethanol, and cleared
through 3 changes of xylene, 5 minutes each. Finally, slides were mounted and
examined under the microscope.
2.10 Determining EBV Gene Expression Using Immunohistochemistry
Once EBV infection in the brain was revealed using EBER-ISH, we aimed at
determining EBV viral gene expression in cases with heavy infection (>200 EBV
positive cells). Immunohistochemistry (IHC) for EBV latent protein EBNA1 and EBV
lytic protein BZLF1 was performed as follows:
1- Tissue sections were briefly heated in 60˚C dry oven for 20 minutes, dewaxed in
xylene and rehydration in graded ethanol.
2- Because peroxidase-catalyzed IHC was performed, slides were incubated in 0.5%
H2O2 in methanol for 20 minutes, to eliminate non-specific background staining.
3- Slides were washed in water and incubated for optimized heat-induced antigen
retrieval (explained in section 2.10.1).
4- Slides where washed in water and incubated with 150-200 µl 5% bovine serum
albumin (BSA) in 1xPBS in humidified chamber for 2 hours, to diminish
background/ non-specific staining. Slides were incubated in the washing buffer,
1xPBS- 0.1% Triton X-100 (Sigma, T-8787) for 5 minutes.
5- Primary antibodies were titrated (table 2.4) to determine best working dilution.
Mouse anti-EBNA1 (clone D810H, Thermo) and anti-BZLF1 (clone BZ1, Santa
Cruz) were diluted 1:100 and 1:10, respectively in the washing buffer. Each tissue
section was incubated with 150-200 µl of diluted primary antibody in humidified
chamber at 4˚C overnight. Slides were washed the following day in 3 changes of
the washing buffer, each for 10 minutes.
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6- Tissue sections were then incubated with 150-200 µl of the secondary anti-mouse
antibody, diluted at 1:200 in the washing buffer in humidified chamber at room
temperature for 1 hour. Slides were washed in 3 changes of the washing buffer.
7- The ABC, DAB and counterstaining steps were carried out as described earlier in
section 2.8, from step 11 onwards.
8- Quality control for immunostaining with anti-EBNA1 and anti-BZLF was
checked by including negative control slides which were incubated with nonimmune sera as a substitute of primary antibodies. B95-8, a replication-permissive
cell line, was also included as a positive control tissue.
2.10.1 Optimizing antigen retrieval
Formalin fixation is well known to cause cross-linking of proteins in a tissue,
let alone tissues aging in formalin, where by-products of prolonged fixation bind, mask
or intervene with the structure of certain antigen epitopes [282]. This progressively
decreases either the accessibility of the primary antibody to the target antigen, or the
recognition of the primary antibody of the target antigen. In other words, antigen
masking hinders antibody-antigen interaction and the ability to detect a particular
antigen epitope in a tissue [282]. This has led to the birth of the concept of antigen
retrieval (or antigen unmasking) for IHC when using formalin fixed tissues [283].
Some of the crosslinking effect can be reversed through certain chemical reactions
such as heating and enzymatic reactions [284]. Heating [285] and applying the right
pH [286, 287] is commonly used for retrieving formalin fixed antigens. Prior to
applying

primary

antibody

we

tried

multiple

approaches

to

optimize

immunorecognition and enhance the signal obtained with IHC staining. These
approaches included:
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1- No antigen retrieval
2- Antigen retrieval using either discontinuous or continuous heating. Slides were
immersed in a pre-boiled 10mM sodium citrate- 0.1% Triton X-100 pH 6.0 and
heated in a domestic microwave for:
a- three cycles of 3 minutes each
b- two cycles of 6 minutes each
c- one cycle of 10 minutes
3- Comparing 2 sources of heat, microwave and hot plate. Slides were immersed in
a pre-boiled 10mM sodium citrate- 0.1% Triton X-100 and heated for 10 minutes
either in a domestic microwave at the highest power or on a hot plate at 150200˚C.
4- Comparing 2 antigen retrieval solutions, 10mM sodium citrate- 0.1% Triton X100 pH 6.0 and 25mM Tris-HCl- 0.1% Triton X-100 pH 9.0. Slides were kept in
the antigen retrieval solution on bench top till the temperature of the solution
dropped to room temperature, then washed in water.
2.11 Identifying the Phenotype of EBV Infected Cells Using Double Staining
To determine the identity of EBV infected cells in the brain, cases with heavy
infection were immunostained for some of the highly suspected cells based on cellular
morphology observed in H&E staining. Following the above described IHC steps,
tissues were incubated with anti-CD3 (a marker for T cells), anti-CD19 and anti-CD20
(markers for B cells). All primary antibodies were titrated to determine optimal
dilution (table 2.4). Anti-CD3 (clone PC3/188A, Santa Cruz), anti-CD19 (clone LECD 19, Thermo), and anti-CD20 (clone L26, Thermo) were diluted 1:100, 1:100 and
1:500, respectively. The quality of immunostaining was checked by including sections
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from a human tonsil as positive tissue control. For negative controls sections were
incubated with 1:200 diluted normal horse serum in 1xPBS instead of the primary
antibody.
To further investigate the phenotype of cells infected with EBV in the brain,
immunofluorescence staining (IF) was performed as follows:
1- Slides were deparaffinised in xylene, hydrated in graded ethanol, and blocked for
endogenous peroxidase activity. Heat-induced antigen retrieval was then
performed.
2- Slides were incubated with 5% blocking BSA for 2 hours and washed
subsequently in the washing buffer (1xPBS-0.1% Triton X-100).
3- Tissue sections were incubated with either rabbit anti-GFAP (glial fibrillary acidic
protein, a marker for astrocytes, Dako) diluted 1:4000, or goat anti-Iba1 (ionized
calcium-binding adapter molecule I, microglial marker, Abcam) diluted 1:500 in
washing buffer. Incubation with primary antibodies was done at 4˚C overnight.
Slides were washed the following day in 3 changes of the washing buffer.
4- Tissue sections were incubated with fluorochrome-conjugated secondary
antibodies for 1 hour at room temperature in the dark. Anti-rabbit- CY5 (Cy™5
AffiniPure Donkey Anti-Rabbit IgG (H+L), Jackson ImmunoResearch, Code:
711-175-152) and anti-goat-rhodamine (Rhodamine Red™-X AffiniPure Donkey
Anti-Goat IgG (H+L), Jackson ImmunoResearch, Code: 705-295-147), were each
diluted 1:100 in the washing buffer. Sections were washed in the washing buffer.
5- Slides were rinsed in 1xPBS, mounted (Immu-Mount, Shandon, 238402), and
visualized in a fluorescent microscope (Olympus BX51) using appropriate filters.
IF slides were stored in the dark at 4˚C.
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We also used two-step IHC and one-step EBER-ISH to co-localize both
EBERs and cellular markers in heavily infected cases.
1- IHC staining for CD20 was carried out as described above. Once DAB/hydrogen
peroxide was applied, tissues were washed, dehydrated in absolute ethanol and
allowed to air dry.
2- Tissue sections were briefly digested with proteinase K (as explained in section
2.8, step 3).
3- Tissue sections were hybridized overnight with labelled EBER probes, and
stringency wash was carried out the following day as detailed above (section 2.8).
4- Tissue sections were incubated with anti-DIG-alkaline phosphatase conjugated
antibody at 1:1000 dilution for 1 hour at room temperature. Slides were washed
in 1x PBS.
5- Sections were incubated with ready-to-use Alkaline Phosphatase chromogen
solution; BCIP-NBT (BCIP: 5-bromo-4-chloro-3-indolyl phosphate NBT: pnitroblue tetrazolium chloride) (ab7468). To select the optimal incubation period
that resulted in the right stain and minimal background, tissues were incubated
with BCIP-NBT for a varying amount of time (40 minutes, 60 minutes, 80
minutes, and 4 hours). Optimal blue stain was developed at 80 minutes incubation.
6- Slides were washed in distilled water, rinsed in 95% ethanol, and briefly stained
with Eosin Y. Sections were then differentiated, dehydrated in absolute ethanol,
cleared in xylene and mounted.
Additionally, parallel triple staining of fluorescence EBER-ISH (FISH) and
immunofluorescence (IF) was carried out:
1- Deparaffinised and hydrated slides were blocked for endogenous peroxidase
activity followed by heat-induced antigen retrieval.
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2- Tissue sections were dehydrated and hybridized with labelled EBER probes.
Stringency washes were carried out the following day.
3- Tissue sections were blocked using 5% BSA.
4- Three primary antibodies were applied simultaneously; mouse anti-DIG, rabbit
anti-GFAP, and goat anti-Iba1 at optimized dilutions. Tissue sections were
incubated overnight at 4˚C, and washed the following day.
5- Slides were incubated in the dark for 1 hour at room temperature with
fluorochrome-conjugated secondary antibodies; Alexa Fluor® 488 AffiniPure
Donkey polyclonal Anti-Mouse IgG (H+L) (Jackson ImmunoResearch, Code:
715-545-151) diluted at 1:200, polyclonal anti-rabbit- CY5 conjugate and
polyclonal anti-goat-rhodamine red conjugate diluted as previously mentioned.
6- Slides were washed, mounted and visualized in a fluorescent microscope.
Antigen

Antibody type (clone)

EBNA1

Unconjugated mouse mAb IgG1,
(clone D810H)
Unconjugated mouse mAb, raised in
mouse (clone BZ1)
Unconjugated mouse mAb IgG1
(clone PC3/188A)

BZLF
CD3

CD19
CD20
DIG
DIG

GFAP
Iba1

Unconjugated mouse mAb IgG1
(clone LE-CD 19)
Unconjugated mouse mAb
IgG2a,кappa (clone L26)
Unconjugated mouse mAb (clone
D1-22)
Alkaline phosphatase conjugate
mouse mAb IgG1 (clone D1-22)
Rabbit polyclonal Z0334 Ig fraction
Goat polyclonal IgG

Optimal Dilution
(titrations tried)
1:10 (1:10, 1:25, 1:50)
1:100 (1:25, 1:50,
1:100)
1:100 (1:100, 1:200,
1:500)
1:100 ( 1:100, 1:200)
1:500 (1:200, 1:300,
1:500)
1:2500
1:1000 (1:500,
1:1000, 1:2000,
1:2500)
1:4000
1:500

Source
Thermo Fisher
Scientific
Santa Cruz
Biotechnology, Inc.
Santa Cruz
Biotechnology, Inc.
Thermo Fisher
Scientific
Thermo Fisher
Scientific
Sigma
Sigma

Dako
Abcam (ab5076)

Table 2.4: Primary antibodies used for different staining protocols
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Chapter 3: Results
3.1 Optimization of DNA Extraction from Formalin Preserved Tissues
Using traditional phenol-chloroform methodology, genomic DNA was
successfully extracted from 8 brain slices (5 white matter and 3 meningeal areas).
Fixation period for these samples ranged between 5 and 16 years. The amount and
purity of genomic DNA recovered were reasonably good. Mean amount of extracted
DNA (±SD) was 545±368 ng/µl (range: 177 ng/µl- 1.6 µg/µl) and mean purity
(expressed as 260/280 ratio) was 1.70±0.2 (range: 1.3-2.0). However, PCR
amplification of a small fragment of the house-keeping gene human β-globin (104 bp)
was inhibited in all 8 samples. Positive control DNA extracted from B95-8 cell line
using the phenol-chloroform method, successfully amplified β-globin fragment,
indicating that inhibition of PCR observed with brain DNA might be a consequence
of sample inherent inhibitor. A 100 ng DNA from each of the 8 samples was seeded
with an equal amount of B95-8 cell line DNA to assess the extent of PCR inhibition.
The magnitude of PCR inhibiton seemed relatively large, as half of the samples (4 out
of 8) inhibited PCR amplification of β-globin fragment (figure 3.1).

Figure 3.1: PCR amplification of β-globin (104 bp). DNA from 8 brain samples were
seeded with 100 ng of positive control DNA at 1:1 ratio. M: 100bp DNA marker, ‘-‘:
negative control (DNA-free water), ‘+’: positive control (B95-8 cell line DNA), E:
empty well [275]
Two of the brain DNA samples that inhibited β-globin amplification (despite
seeding with the positive control) were seeded with a serial dilution of B95-8 cell line
DNA. The signal was detected in both samples when brain DNA amount was reduced
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(from 100) to 50 ng and seeded with an equal amount of B95-8 cell line DNA. This
suggested that the magnitude of PCR inhibition might depend on the amount of brain
DNA used as a template. As the amount of B95-8 cell line DNA serially declined, the
intensity of PCR signal decreased as well, and the inhibitory effect of brain DNA
seemed more conspicuous. However, the signal was still detectable at the lowest
concentration of B95-8 cell line DNA. This indicated that inhibition caused by 50 ng
brain DNA was minimal but sufficient to cause PCR inhibition of brain DNA on its
own (figure 3.2).

Figure 3. 2: Seeding brain DNA with positive control. PCR amplification of β-globin
(104 bp) in 2 brain samples. Seeding 50 ng of brain DNA with a serial dilution of
positive control (B95-8 cell line) DNA. 1 and1`: 50 ng brain DNA+ 50 ng B95-8
DNA, 2 and 2`: 50 ng brain DNA + 25 ng B95-8 DNA, 3 and 3`: 50 ng brain DNA +
12.5 ng B95-8 DNA, 4 and 4`: 50 ng brain DNA + 6.25 ng B95-8 DNA, 5 and 5`: 50
ng brain DNA + 3.125 ng B95-8 DNA. M: 100 bp DNA marker, ‘-‘: negative
control, ‘+’: positive control, E: empty well
To overcome PCR inhibition, different commercial kits for DNA extraction
were tried. Compared to phenol-chloroform method, DNA extraction kits recovered
relatively smaller amounts (mean: 20±3 ng/µl), and lower purity (mean 260/280 ratio:
2±0.2) of brain DNA. PCR amplification of human β-globin was inhibited in most of
the samples (figure 3.3).
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Figure 3.3: DNA extracted using different protocols. PCR amplification of β-globin
in brain DNA. Samples 1- 8 were extracted using commercial extraction kits.
Samples 9-13 were extracted using phenol-chloroform method after processing,
paraffinising and deparaffinising brain tissue. M: 100 bp DNA marker, ‘-‘: negative
control, ‘+’: positive control, E: empty well
Because formalin is known to cause inhibition of PCR amplification we tried
to eliminate as much formalin as possible from brain tissues. During tissue processing
for paraffin embedding, tissues were exposed to series of dehydration and clearing
steps. The rationale behind tissue processing was to remove formalin from fixed brain
tissues, which might help overcome PCR inhibition. Five brain tissues were processed,
paraffinised, and deparaffinised. Mean amount and purity of DNA extracted from the
5 samples (using phenol-chloroform method) was 284±150 ng/µl and 1.7±0.1,
respectively. Despite tissue processing before DNA extraction, inhibition of PCR
amplification of β-globin persisted (figure 3.3).
We also tried 3 concentrations of the chelating agent MgCl2 in the PCR
mastermix to find the optimal concetration that could optimize the activity of Taq
DNA polymerase and hence PCR amplification. Although 2 mM MgCl2 was efficient
in amplify positive control DNA, PCR inhibition remained in brain DNA using either
2, 3 or 4 mM MgCl2. Substituting MgCl2 with Q solution (provided with Qiagen Taq
PCR), however, reduced PCR inhibition as weak signals appeared in few samples
(figure 3.4). Therefore, adding Q solution was adopted for all the subsequent PCR
reactions.
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Figure 3.4: Using different concentrations of MgCl2. Q solution was added in PCR
mastermix of 4 samples (1-4). Three of these 4 samples had MgCl2 in PCR
mastermix of varying concentrations; 2, 3 and 4 mM. M: 100 bp DNA marker, ‘-‘:
negative control, ‘+’; positive control, E: empty well
3.1.1 Defining PCR inhibitor(s)
It was noticed that DNA extracted using phenol-chloroform method contained
whitish pellet. The white precipitate was thought to be a possible PCR inhibitor,
potentially related to salted DNA precipitation step. Thus, we substituted sodium
acetate with sodium chloride. The white pellet was eliminated when DNA was
precipitated using NaCl, but PCR was still inhibited.
Beside formalin, several chemicals used during DNA extraction such as SDS
and chloroform, could be co-extracted and cause PCR inhibition. To reduce DNA
contamination with formalin, tissues were thoroughly washed in several (6-10)
changes of washing buffer. Although this improved PCR amplification signal in some
samples, yet PCR inhibition still existed in most of the samples.
Moreover, the amount of SDS, an essential detergent to lyse cell membrane for
DNA extraction, was reduced from 1% to 0.1%. Genomic DNA was extracted from 5
weight-equal brain samples, and each sample was represented by 2 replicas. One DNA
replica was extracted using 1% SDS and the second replica was extracted using 0.1%
SDS, keeping all other extraction parameters fixed. A 10-fold decrease in SDS amount
brought noticeable improvement of PCR amplification, as all the 5 samples treated
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with 0.1% SDS showed PCR signal for human β-globin compared to only 3 out of 5
samples treated with 1% SDS (figure 3.5).

Figure 3.5: Using different amounts of SDS. PCR amplification of 104 bp- β-globin
(β-G) in 5 weight-equal brain samples, incubated with digestion buffer that contained
1% or 0.1% SDS. Other extraction parameters were kept constant. ‘-‘: negative
control, ‘+’: positive control, E: empty well [275]
To ensure consistent PCR-amplifiable quality of DNA, a number of positive
changes in DNA extraction protocol were subsequently implemented:
1- Thorough washes of brain tissues in 1xPBS, to eliminate the fixative.
2- DNA precipitation using 0.1 M NaCl.
3- Using 0.1% SDS in digestion buffer.
3.1.2 Optimising digestion conditions
3.1.2.1 Proteinase K concentration
Other factors that govern DNA quality and quanitiy were revised to obtain the
best quality DNA from archival formalin fixed material. Proteinase K, an important
determinant of DNA quality and quantity, digests cellular proteins, nucleic acidassociated proteins and some DNases [288]. To determine the best concentration of
proteinase K, 4 weight-equal brain samples (each sample had 5 replicas) were digested
at 55˚C with 5 different concentrations of proteinase K in parallel incubation setups
for 24 hours. DNA purity was invariable between tissues digested with different
concentrations of proteinase K. Highest yield of DNA (111 ng/µl) was recovered when
tissues were digested with the highest concentration of proteinase K (2.5 mg/ml), while
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the lowest yield (60 ng/µl) was recovered when tissues were digested with the lowest
concentration of proteinase K (0.15 mg/ml) (figure 3.6 A). PCR-amplifiable quality of
the extracted DNA was also checked. The best signal of β-globin amplification was
achieved with DNA digested with 0.62 mg/ml proteinase K. Despite the highest yield
obtained from tissues digested with 2.5 mg/ml proteinase K, PCR signal was
comparatively weak (figure 3.6 B). In general, digesting tissues with 0.62 mg/ml
proteinase K for only 24 hours was sufficient to extract PCR amplifiable DNA with
mean yield of 67±15 ng/µl (figure 3.6 C). Since a concentration of 0.5 mg/ml (within
the optimal range of enzyme activity) was previously shown to result in good quality
and quantity of DNA, it was applied in all the subsequent experiments.

Figure 3.6: Using different proteinase K concentrations. Four weight-equal brain
tissues were digested with 5 different proteinase K concentrations concurrently. A)
Mean DNA yield obtained when digesting tissues with 5 different proteinase K
concentrations (bars). Long standard error bars indicate high variability in DNA
yield between samples within the same group. The big intra-group variation in DNA
yield might reflect samples variation in postmortem interval and length of formalin
fixation, both of which are factors known to determine amount of DNA extracted
from a given tissue. B) PCR amplification of 104 bp-β globin fragment in the 5
groups treated with a given proteinase K concentration. C) Mean band intensity of
amplicons within a same group as semi-quantitatively determined using Image J
software. ‘-‘: negative control, ‘+’: positive control, E: empty wells [275]
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3.1.2.2 Digestion length
Tissue digestion could also be optimized by regulating the length of digestion.
Twenty six randomly selected brain tissues were digested with 0.5 mg/ml proteinase
K at 3 different time lengths (table 3.1). Length of formalin fixation did not vary
between the selected tissues. In the first group, 8 tissues were digested for 39 hours
and produced 106±68 ng/µl DNA. In the second group, 10 tissues were digested for
68 hours. This longer digestion period resulted in higher DNA yield (mean DNA
amount was 118±50 ng/µl). Eight tissues in the third group were digested for 116
hours. DNA yield was highest in this group (mean of 341±132 ng/µl). The purity of
extracted DNA did not differ between the 3 groups.
Length of digestion
No. of cases
Mean fixation length
Mean DNA yield
Mean 260/280 OD

39 hours
8 cases
11±7
106±68
1.60±0.1

68 hours
10 cases
14±8
118±50
1.60±0.05

116 hours
8 cases
13±6
341±132
1.70±0.05

Table 3.1: Properties of DNA extracted from tissues digested at 3 different lengths.
Mean fixation length in years. Mean DNA amount in ng/µl
To evaluate DNA quality (i.e. extent of DNA fragmentation), 5 DNA samples
from each group were electrophoresed on 2% agarose gel. DNA was remarkably
fragmented, with most of the fragments being less than 200 bp (figure 3.7 A). Tissues
digested for 68 hours showed better DNA smear pattern compared to tissues digested
for 39 and 116 hours. Thus, we checked PCR amplifiability of DNA extracted from
all ten tissues digested at 68 hours using primers for house-keeping genes of 3 different
lengths (104 bp β globin, 351 bp GAPDH, and 560 bp GAPDH). In consistence with
DNA gel electrophoresis results, the small fragment, 104 bp β globin, was amplifiable
in all 10 DNA samples (figure 3.7 B). However, the signal was lost in ~ 1/3rd of the
samples when amplifying a slightly larger fragment, 351 bp GAPDH. More than half
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of the samples could not amplify a fragment that is over 500 bp. Therefore, primers
flanking small DNA sequence (less than 200 bp) were used to assess both PCR internal
control and presence/absence of EBV viral DNA in formalin preserved brain tissues.

Figure 3.7: Testing DNA quality. DNA was extracted from tissues digested at 3
different lengths. (A) Quality of DNA was tested on 5 samples from each digestion
length group. (B) PCR amplifiability of DNA extracted from ten tissues digested for
68 hours. M: 100 bp DNA marker, ‘-‘: negative control, ‘+’: positive control, E:
empty well [275]
3.1.2.3 Final optimized extraction protocol
Eventually, genomic DNA extraction from long-term formalin fixed and
preserved human brain tissues using phenol-chloroform method was formulated into
the following optimized steps:
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1- A small piece of brain tissue was extensively washed in 6-10 changes of 1xPBS
buffer.
2- Tissues were homogenized and incubated with a digestion buffer containing
500mM TRIS, pH 9.0; 20mM EDTA, 10mM NaCl, 0.1% SDS and 0.5 mg/ml
proteinase K, at 55 °C for 68 hours.
3- Tissue lysate, then, underwent phenol-chloroform biphasic extraction.
4- DNA in the upper aqueous phase was transferred to a new sterile tube, and
precipitated in cold absolute ethanol using 0.1M NaCl.
5- Precipitated DNA was washed with cold 70% ethanol, air dried, and
resuspended in TE buffer.
PCR amplification was further enhanced by using primers flanking small
fragments of less than 200 bp and adding Q solution in PCR mastermix.
3.2 DNA Extraction from 1 White Matter and 3 Meningeal Areas
DNA was extracted from all 122 cases using the optimized conditions of
phenol-chloroform extraction protocol, from 2 distinct brain areas, white matter and
meninges. The mean amount of DNA extracted from the white matter (548±457 ng/µl)
was comparable to that extracted from the meninges (514±449 ng/µl) (Table 3.2). All
122 cases had at least 1 replica of meningeal DNA. While 106 cases had 2 replicas, 60
cases had 3 replicas of meningeal DNA, allowing for investigating multiple regions of
the meninges (table 3.2).
Target brain area
No. of cases

White matter
122 cases

Mean DNA yield
Mean 260/280 OD ratio

548±457 ng/µl
1.63±0.3

Meninges
Replica1: 122 cases
Replica 2: 106 cases
Replica3: 60 cases
514±449 ng/µl
1.70±0.1
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Table 3.2: Properties of DNA extracted from all cases. DNA was extracted from
white matter and meninges
Internal PCR control was checked by amplifying human β-globin (104 bp),
which was amplifiable in all the 122 white matter DNA (figure 3.8 A) and meningeal
DNA samples (figure 3.9 A). Meningeal replicas that failed in amplifying β-globin
were excluded from downstream molecular detection of EBV.

Figure 3.8: PCR amplifiability of white matter DNA. A) PCR amplification of βglobin in white matter DNA from MS and non-MS cases. β-globin fragment was
amplifibale in all tested DNA. B) Presence of EBV in the white matter was checked
by amplifying EBV BamHI W fragment. EBV was detected in 15/26 MS and 0/6
non-MS cases. M: 100 bp DNA marker, ‘-‘: negative control, ‘+’: positive, NMS:
non-MS case
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Figure 3.9: PCR amplifiability of meningeal DNA. A) PCR amplification of β-globin
in meningeal DNA from MS and non-MS cases [275]. β-globin fragment was
amplifibale in all meningeal DNA. B) Amplification of EBV BamHI W fragment in
meningeal DNA from MS and non-MS cases. EBV was detected in 6/23 MS and 0/9
non-MS DNA. M: 100 bp DNA marker, ‘-‘: negative control, ‘+’: positive control,
NMS: non-MS case
3.3 Detection of EBV in White Matter
The presence/absence of EBV in white matter DNA was checked by
amplifying a conserved sequence of 152 bp of EBV BamHI W fragment (figure 3.8
B). Overall, 45 cases (37% of all white matter DNA) were EBV positive in the white
matter. Forty-two MS and 3 non-MS cases (41% vs 14% respectively) were found to
be positive. Two of EBV positive non-MS control cases had definitive brain pathology
(dementia with Alzheimer’s disease and progressive tauopathy) at autopsy.
3.4 Detection of EBV in Meninges
With relatively high percentage of EBV positivity in white matter DNA, one
must understand how EBV could gain access to the brain. PCR amplification of EBV
BamHI W fragment was checked in multiple replicas of meningeal DNA (figure 3.9
B). One fourth of all cases (31 cases) was found to be EBV positive in at least one
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meningeal replica. Seventeen percent of the cases were EBV-positive in 2 replicas and
2% were positive in all 3 meningeal replicas. Frequency of EBV positivity in
meningeal DNA was higher in MS cohort (49/101 MS cases) than in control cohort
(3/21 non-MS cases). EBV positive non-MS control cases were characterized with
brain pathologies (meningioma and dementia with Alzheimer’s disease). Overall,
regardless of whether it was white matter DNA or meningeal DNA, standard PCR
revealed EBV positivity in 64 MS cases (64%) and in 5 non-MS control cases (24%).
3.5 Investigating the Presence/Absence of Other Ubiquitous Herpesviruses
To determine whether EBV presence in the brain was preferential and
selective, PCR amplification of small conserved fragments from HSV-1, CMV and
HHV-6 genomes was performed on randomly selected 16 EBV positive white matter.
Primers for these herpesviruses were chosen based on our finding that DNA extracted
from archival formalin fixed materials was of poor quality and could only reliably
amplify fragments of less than 200 bp. Thus, the amplicon size for all three
herpesviruses was less than 200 bp. All 16 samples showed no signal for either HSVI (figure 3.10 A), CMV (figure 3.10 B), or HHV-6 (figure 3.10 C). Few non-specific
bands were seen in PCR amplification of CMV and HHV-6 fragments from 2 DNA
samples. Each sample, then, underwent PCR amplification for CMV and HHV-6
fragments in duplicates, which ultimately were negative for CMV and HHV-6. These
results suggested that EBV presence in the brain might be selective and less likely a
result of non-specific influx into the brain, indicating that EBV may have a role in the
pathogenesis of MS.
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Figure 3.10: PCR amplification of 3 common herpesviruses. 16 EBV positive white
matter DNA were tested. A) HSV fragment (92 bp) was not detected in the white
matter. Positive control DNA for HSV-I was extracted from a clinical sample with
substantial HSV infection. B) CMV 139 bp fragment was not detected in the white
matter. Positive control DNA for CMV was extracted from a clinical sample with
heavy burden of CMV infection. C) All 16 DNA samples were also negative for
HHV-6 137 bp fragment. PCR was repeated for samples that showed non-specific
bands to confirm the negative results. M: 100bp DNA marker, ‘-‘: negative control,
‘+’: positive control DNA, E: empty well
3.6 Quantitation of EBV Load in EBV Positive Cases
To estimate viral load in EBV positive white matter and meningeal DNA, we
performed real-time (quantitative) PCR. DNA extracted from Namalwa cells, serially
diluted in nuclease-free water was used as a standard to quantify EBV copy numbers
in our test samples. Namalwa cell line was used to establish the standard curve as
follows:

91

1- DNA was extracted from 1x106 viable cells. This resulted in 11.2 µg DNA,
equivalent to 89.29 Namalwa cells per 1 ng DNA.
2- Since Namalwa cells have two EBV copies integrated per cell [280], 1 ng DNA
(89.29 cells) contained 178.57 EBV copies.
Five dilutions of Namalwa DNA were used: 1x102, 1x101, 1, 1x10-1 and 1x10-2
ng/reaction, representing 17857, 1785.7, 178.57, 17.857, 1.7857 viral copies,
respectively (table 3.3). Using TaqMan real-time PCR amplification of EBV BamHI
W region, mean Ct values were determined for each Namalwa DNA concentration.
Subsequently, individual mean Ct values (Y-axis) were plotted against the log EBV
known copy numbers (X-axis) (figure 3.11). The slope of the linear curve which
reflected cycle difference for the 5 Namalwa DNA concentrations was estimated to be
3.4605.
Namalwa (standard)
DNA

Mean Ct

Number
of cells

EBV copy
number

Log EBV copy number

100 ng/reaction

22.256

8929

17857

4.251808499

10 ng/reaction

25.108

892.9

1785.7

3.251808499

1 ng/reaction

28.39

89.29

178.57

2.251808499

0.1 ng/reaction

33.203

8.929

17.857

1.251808499

0.01 ng/reaction

35.511

0.8929

1.7857

0.251808499

Table 3.3: Dilutions of Namalwa DNA and their Ct values
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Figure 3.11: Standard curve for qPCR. The curve was established using Namalwa
DNA. Five 10-fold serial dilutions of Namalwa DNA (X-axis) were plotted against
individual mean Ct values (Y-axis). The linear equation: y = -3.4605x + 36.686, R² =
0.9896
Using Namalwa standard curve, EBV viral load was quantitated in the brain.
Amplification that took place at or above mean Ct value of 34 (less than 10 EBV copies
per 100 ng DNA) were considered very low or undetectable levels. EBV copy number
was calculated for each test sample using the equation:
EBV copy number = 10 Ct sample – intercept
Slope
Of the 45 white matter DNA samples, 40 had measurable EBV load ranging
from 16,823 to 157 copies per µg DNA. EBV copy number between 100 and less than
1,000 copies per µg DNA was considered low viral load, while a copy number between
1,000 and less than 2,000 EBV copies per µg DNA was considered moderate viral
load. More than half of the samples had moderate viral load (table 3.4). Only 3 samples
had more than 2,000 EBV copies per µg DNA, and this was considered relatively high
viral load. Overall, mean EBV load in white matter DNA was 1,556 ± 2,608 EBV
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copies per µg DNA. The variation noticed in EBV load in the white matter could partly
be due to varying number of reiteration of BamHI W region (7 to 11 repeats per EBV
copy; varying between different EBV strains). Also, any potential difference between
EBV strain in Namalwa cells and that in the brains could possibly affect the precision
of EBV quantification [138]. However, targeting a sequence that has multiple repeats
in each EBV genome makes up the great sensitivity of the assay to detect low-level
EBV.
Level of viral load

Median EBV
load
515

Mean EBV load

Low (100 ≤ EBV copies/ µg DNA < 1k)

Number
of cases
16

Moderate (1k ≤ EBV copies/ µg DNA < 2k)

21

1,248

1,431±320

High (≥2k EBV copies/ µg DNA)

3

4,927

7,923 ±7,844

Total

40

1,157

1,556 ± 2,608

525±279

Table 3.4: A summary of EBV load in white matter DNA. EBV load: viral copies/
µg DNA. Mean EBV load in white matter DNA was expressed as mean ±SD
Similarly, EBV was quantified in EBV positive meninges (2 and 3 replicas
were pooled into one 50 ng/µl aliquot). Only one of the 19 meningeal DNA had
detectable (168 copies/ µg DNA) viral level, suggesting that EBV signal (in
conventional PCR) might have emanated from occasional EBV-harboring cells, which
had survived the harsh conditions of DNA extraction. The undetectable viral load was
consistent with PCR weak bands.
3.7 Histopathology of MS Lesions
A total of 358 paraffin blocks from the white matter/ white matter-grey matter
junction (brain parenchyma), and 257 meningeal blocks (total 615 blocks) represented
all 122 MS and non-MS cases. Each case had sections stained for histopathological
evaluation by an in-house pathologist. Brain pathology in MS cases was confirmed
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based on H&E staining. Tissue abnormalities in non-MS cases that had other
neurological disorders such as Alzheimer’s disease, Parkinsonism and meningioma
were confirmed. MS cases showed variable histopathological features, including but
not limited to mild leptomeningeal inflammation, fibrous sharply demarcated plaques,
wide-spread perivascular and parenchymal inflammation, gliosis, lipid-laden
macrophages and hypo- or hyper-cellularity depending on lesion activity (figure 3.12).
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Figure 3.12 Histopathological features of MS lesions. a) Hypocellular fibrotic lesion
b) Oedematous lesion with marked myelin vacuolation (arrowhead) adjacent to
perivenous inflammation c) Widespread perivascular and parenchymal immune
infiltration. d) Gliosis. e) Intense inflammation in the meningeal layers. f) Multiple
MS lesions with well-demarcated margin and demyelinated centre
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3.8 Quality Control for EBER-ISH
EBER-ISH is considered the ‘gold standard’ for localizing EBV infected cells
in a given tissue, and is often used to visualize the source of EBV positive signal
obtained with PCR. Sections from 615 paraffin blocks were stained for EBER-ISH.
For EBV positive control, tonsil tissue from a patient diagnosed with EBV infectious
mononucleosis (IM) was used. The EBV-IM tonsil paraffin block was a kind gift of
Prof. Gerald Neidobitek, Institute of pathology, Berlin. Using labelled EBER antisense
probe, EBER-positive cells were easily spotted in IM tonsillar tissue as abundant
specific brown nuclear staining cells scattered throughout the tissue (figure 3.13 a).
EBER-positive cells had small to medium-sized nuclei with characteristic stainingfree nucleoli, and a morphology typical of lymphoid cells (figure 3.15, note at highpower view). Specificity of EBER-ISH staining was ensured by using EBER sense
probes, which were non complementary to EBER sequences and hence not expected
to bind to the target EBERs. Additional negative controls constituted of performing
EBER-ISH on sections that had been pre-treated with RNase A (figure 3.14).
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Figure 3.13: EBER-ISH on IM tonsil. a) Low-magnification view showing widely
disseminated EBV infected cells (scale bar 100µM). b) A closer view at welldistributed, easily detectable EBV infected cells (scale bar 50µM). c) and d) Highpower view, note the characteristic nuclear EBER staining (scale bar 20µM)

Figure 3.14: Testing specificity of EBER-ISH. Quality control for specificity of
EBER probes was confirmed using EBER sense probes. No staining was revealed
with these negative controls for EBER-ISH. Left panel showing low-magnification
view (scale bar 50 µM), and on the right higher magnification view (scale bar 20
µM). Using RNase A treatment prior to hybridization with EBER antisense probes
also consistently gave no signal (not shown)
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3.9 Localization of EBV Infected Cells in the Brain
Once the quality control of EBER-ISH was ensured, all brain sections from
both MS and non-MS cases were stained for EBER-ISH. All sections were screened
carefully under light microscope to avoid missing single positive cell. For analysis
purpose, EBER-positive cells were counted manually in EBV-positive sections (mean
dimension 1.5 x 1 cm). In sections representing brain parenchyma, EBER-ISH
revealed positivity in 80/101 MS cases and in 5/21 non-MS cases. While in meningeal
sections, positivity was found in 60 MS cases and in 3 non-MS cases. In total, 83 MS
cases (83%) and 5 non-MS cases (24%) were positive for EBV by EBER-ISH.
Correlation between EBV positivity and type of MS, age at death, sex, and disease
duration could not be established due to lack of available data. In non-MS control
tissues, however, EBV positivity was mainly in cases with documented neurological
disorders (meningioma, dementia, and progressive supranuclear palsey-like
Tauopathy). Also, in most cases EBER positivity was seen in lymphocyte-like cells.
Occasionally, EBER positive cells with morphology not typical of lymphocytes were
also seen (figure 3.15 -3.18).
Positivity for EBV in the white matter was categorized into 3 categories; ‘+’
for sections containing 1-49 positive cells, ‘++’ for sections containing 50-200 positive
cells, and ‘+++’ containing over 200 positive cells. Forty MS cases were categorized
as ‘+’, 29 MS cases as ‘++’ and 19 MS cases as ‘+++’ (heavily infected cases). It is
noteworthy that the MS case which had the highest viral load as determined by qRTPCR, was also amongst the cases which had the highest number of infected cells by
EBER-ISH. Multiple tissues from this case were examined and all were consistently
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found to be EBV positive. Furthermore, meninges from this case was also found to be
EBV positive (see ahead).

MS95- antisense probe

MS95- sense probe

Figure 3.15: EBER-ISH on case MS95. EBV infected cells were localized in brain
parenchyma, which showed ‘++’ positivity (using antisense probe). Sections from
the same case hybridized with EBER sense probe gave negative signals. Original
magnification 40x

MS17- antisense probe

MS17- sense probe

Figure 3.16: EBER-ISH on case MS17. EBV infected cells scattered (++) in brain
parenchyma in a case of severe MS with chronic inactive lesions. Using EBER sense
probe resulted in signal elimination ensuring probe specificity. Original
magnification 40x
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MS63- antisense probe

MS63- sense probe

Figure 3.17: EBER-ISH on case MS63. This case represented RRMS with
predominance of chronic inactive lesions. This case showed wide distribution of
EBER positive cells (heavily infected case). These cells resided adjacent to/ part of
perivascular infiltration and parenchymal inflammation. Positive signals were
eliminated using EBER sense probe. Original magnification 40x

NMS21- antisense probe

NMS21- sense probe

Figure 3.18: EBER-ISH on case non-MS21. EBER signal was seen in this control
case (meningioma case), showing positivity in lymphocyte-like cells and other
morphologically distinct cells. Using sense probe ensured staining specificity.
Original magnification 40x
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3.10 Determining Entry Route of EBV into the Brain
Several reports have discussed the role for the immunopathology of meninges,
particularly meningeal inflammation in the pathogenesis of different stages of multiple
sclerosis [289-293]. Meninges were investigated as a potential route of EBV and
stained for EBER-ISH. In many MS cases, meninges had little or no cellular
component and only fibrous connective tissue could be seen. Similarly, control cases
lacked any visible inflammation. Therefore, positive signals for EBERs were hardly
detectable in such sections.
EBER-ISH revealed positivity in lymphocyte-like cells infiltrating the
meninges in at least one replica in 60/101 (59%) MS cases where mild to moderate
meningeal inflammation was observed. In the non-MS control cohort, 3 cases (14%)
which were found positive for EBERs in brain parenchyma, were also positive for
EBERs in the corresponding meningeal sections (figure 3.19). It was commonly
noticed that EBERs positivity in the meninges corresponded to that in brain
parenchyma but not vice versa.
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Figure 3.19: EBER-ISH on MS meninges. Case MS47 was used as a representative
for EBER positivty obtained in inflamed the meninges (a and b). EBER sense probe
was consistenly used to ensure signal specificity (c). Original magnification of lowpower view 10x, and high- power view 40x
3.11 Correlating EBV Positivity in the Brain Using PCR and ISH
Utilizing two different techniques in detecting EBV in two different regions of
the brain provided strength for the obtained data, because each technique has -to some
extent –compensated for the limitations of the other one. The following conclusions
have been drawn from the overall data:
1- Taken all together, both techniques revealed positivity in 90% of MS cases vs
24% non-MS control cases (figure 3.20).
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2- EBER-ISH appeared more sensitive than PCR, because EBER-ISH revealed
positivity in 83% MS cases, while PCR data showed positivity in 64% MS cases.
Fivty seven of these cases were found positive by both techniques (figure 3.21).
3- EBV positivity was found to be higher in brain parenchyma than in meninges
(87% vs 80% respectively). Seventy-seven percent of MS white matter was found
EBV positive by both techniques (figure 3.22).
4- Assessing the sensitivity of each technique in each brain region, EBER-ISH was
found more sensitive than PCR in detecting positive signals in brain parenchyma
(79% vs 41% respectively). Less dramatic difference between the techniques was
seen in the meninges; as positivity revealed by ISH was 58% compared to 49%
by PCR (figure 3.23).

Figure 3.20: EBV prevalence in MS and control cases. EBV positivity in MS cohort
(right) and non-MS control cohort (left) was revealed by PCR and ISH. Ctrl: control
cohort (non-MS cases)
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Figure 3.21: EBV positivity in MS cohort revealed by PCR and ISH

Figure 3.22: EBV positivity in two regions of the MS brain. WM: white matter, M:
meninges

Figure 3.23: Sensitivity of PCR and ISH. Detection power of the techniques was
dissected according to brain region, white matter and meninges
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3.12 Optimization of Antigen Retrieval
In order to obtain the most sensitive and specific signals for the detection of
viral and cellular antigens using immunohistochemistry (IHC), multiple approaches of
antigen retrieval were tested. Untreated sections from both tonsil control tissue and
brain tissues gave false negative signal for both cellular and viral proteins. Heatinduced antigen retrieval was tried using pre-boiled sodium citrate (pH 6.0) buffer
[294] in a domestic microwave [283, 295], for different time lengths [296]. IHC
staining signal was not detected in control tissues heated for 3 minutes, while heating
for continuous 10 minutes resulted in background and several non-specific staining in
brain tissues. These problems were less severe in control tonsil tissue, because it was
not exposed to over-fixation in formalin. Using two 6 minute-cycles of heating,
antigens were well-retrieved in control tissues (figure 3.24) but background and nonspecificity persisted in brain tissues. Using 3 cycles of heating, each for 3 minutes,
resulted in detachment of brain tissue sections from the coated slides, or in non-specific
staining.
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Figure 3.24: Effect of heating on antigen retrieval. Comparing the effect of
continuous and discontinuous heating was performed on control tissue (human
tonsil) incubated in sodium citrate buffer (pH 6), exposed to high-power microwave
heating for either a) continuous 10 minutes or b) 2 cycles each for 6 minutes.
Discontinuous pattern of microwaving was found to produce enhanced crispness of
CD3 staining in the tonsil. Original magnification 40x
We substituted microwave heating with heating on hot plate. Using hot plate
at high temperatures (150-200 ˚C) eliminated the problem of detachment of brain
tissues that might be due to microwave irradiation. Although this method of heating
gave good staining in control tissue, staining in brain sections was dull and inconsistent
between different cases.
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Moreover, we compared two different pH points of antigen retrieval buffer, pH
6 and pH 9 (Tris-HCl buffer). Using basic buffer together with heating on hot plate led
to a better staining pattern in brain tissues, which was enhanced by increasing the
heating period to 20 minutes. Thus, antigen retrieval for immunohistochemistry for
cellular and viral antibodies that we used was optimized by heating sections:
1- in basic buffer (Tris-HCl, pH 9.2),
2- on a hot plate at high temperatures 150-200˚C, and
3- for 20 minutes. Note that this long exposure to high temperature caused buffer
evaporation so continuous adding of the buffer was required to ensure levels that
covered tissue sections.
3.13 Determining EBV Gene Expression in MS Brain
The presence of EBV in a large proportion of MS cases suggested that virus
may be involved in the pathogenesis of this disease. To further address this, we wanted
to determine what viral genes were expressed in infected cells. We stained two
important EBV genes, the latent antigen EBNA1 and the immediate early gene BZLF1.
The expression of BZLF1 marks the switch from latency to lytic cycle. The quality
control of immunohistochemistry was checked using tonsillar tissue from IM case and
agarose-embedded B95-8 cells. Specificity of the staining was validated using
negative controls (omitting primary antibody) for each section.
The distribution of EBNA1 staining in IM tonsil section showed a similar
pattern of distribution to that seen with EBERs staining (figure 3.25). Unlike EBNA1,
BZLF1 expression was scarce, so spotting BZLF1 positive lymphocytes in a mesh of
lymphocytes within the crowded lymphoid structure was a challenge. Thus using B95-

108

8 cells as a control section for BZLF1 expression proved to be a better control since
single BZLF1 positive cells could be easily seen (figure 3.26).

Figure 3.25: EBNA1 expression in IM tonsil
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Figure 3.26: BZLF1 expression in B95-8 cells. Replication permissive B95-8 stained
for BZLF1 showed a small percentage of scattered nuclear-stained cells
Eighteen MS brain sections with heavy EBV infection (>200 EBER positive
cells) were immunostained for EBNA1 and BZLF1. EBNA1 expression was easier to
detect in brain parenchyma compared to that of BZLF1. Cells expressing EBNA1
ranged in number from 5-19 cells per section (~1-10% of EBER positive cells).
EBNA1 expression was seen in 14/18 brain tissues. Distribution of EBNA1 positive
cells was diffuse, scattered and almost associated with hypercellular parenchyma
(figures 3.27- 3.28).
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Figure 3.27 Expression of EBNA1 in case MS55. Original magnification 40x and
60x

Figure: 3.28 Expression of EBNA1 in case MS63. This RRMS case had higher
expression of EBNA1 with 18 small lymphocyte-like cells. Original magnification
40x and 60x
On the other hand, the level of expression of BZLF1 in the brain tissue was
fairly low (≤ 1%) and could only be detected in 3/18 heavily infected MS cases
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suggesting minimal lytic cycle activity (figure 3.29). The almost global absence of
BZLF1 signal from MS brains does not necessarily translate into lack of lytic cycle in
EBV heavily infected brain tissues, but it could reflect, among other potential reasons,
the negligible level of lytic cycle resulting in missed signal. It might also be due to a
possible association between viral lytic cycle and particular type of MS lesions. There
was insufficient data to establish a correlation between EBV gene expression and
disease type or lesion activity.

Figure 3.29: BZLF1 expression in MS52
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3.14 Phenotypic Characterization of EBV Infected Cells
After

characterizing

EBV

gene

expression

in

the

brain

using

immunohistochemical (IHC) staining, we aimed at characterizing immunophenotype
of EBER positive cells. Distribution and frequency of two prominent contributors to
the immune influx in MS brain, CD3 positive T cells and CD20 positive B cells were
determined using IHC in heavily infected cases. The quality control for CD3 and CD20
immunostaining was ensured by including human tonsil control tissue (figure 3.30).
Consistent with autopsy reports, there was an almost universal absence of
CD19, CD20, and CD3 positive cells in brain parenchyma. Three of the 18 heavily
infected cases tested had visible infiltration of CD3 positive cells and CD20 positive
cells. Limited levels of expression of CD3 and CD20 were found in 2 of these cases,
while widespread distribution of CD3 and CD20 was seen in the third case (RRMS)
(figure 3.31). Substantial expression of these markers were found within brain
parenchyma and around blood vessels (perivascular cuffs). Although H&E staining
showed marked lymphocytosis and gliosis in nearly all of MS sections, many of these
cells which had indeterminate phenotype. Thus suggesting that EBV might be
localized in other distinct phenotypically characterized cells such as microglia,
astrocytes, resident macrophages, or other B cell lineage cells.
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Figure 3.30: Quality control for CD20 and CD3. Immunostaining IM tonsil tissue
showed distribution of CD20-positive B cells (making up germinal centre) (a), and
massive occupation by CD3-positive T cells (b). Original magnification 40x and 60x

114

Figure 3.31: Expression of CD3 and CD20 in case MS63. The majority of small
lymphocyte-like cells stained for CD3 (a and b) and to a lesser extent CD20 (c and
d). Original magnification 10x (a, b), scale bar 100µM (c), original magnification
20x (d)
Because of the heavy infiltration of CD20 positive cells in case MS63 (figure
3.31), we used this case to double-stain for EBERs and CD20. Double staining was
validated in IM tonsil section (figure 3.32). EBER-ISH in this case showed over 200
positive cells in a series of sections. However, the number of EBER positive cells seen
in double staining for EBER and CD20 was very limited (figure 3.33). This could be
due to reduced sensitivity of one-step ISH compared to two-step EBER-ISH. While
several cells were found co-expressing EBERs and CD20 (figure 3.34), some had
EBER signal but were negative for CD20.
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Figure 3.32: Quality control for double staining. CD20 IHC and EBER-ISH in IM
tonsil showed co-localization of CD20 (membrane) brown signal and EBERs
(nuclear) dark blue signal in many cells. (a) Low-power overview, scale bar 50µM.
(b) High-power view Original magnification 40x, zoom-in window 60x
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Figure 3.33 Double staining in case MS63. (a) Individual staining of CD20. (b)
EBER-ISH. (c) Some EBER signals were located in CD20 positive cells. Original
magnification 40x
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Figure 3.34: High power view of double staining in case MS63. Membrane CD20
(brown) and nuclear EBER (dark blue) staining scattered in brain parenchyma.
Original magnification 40x
We also stained for both EBERs and Iba1 (a marker for microglia) in this case
(MS63). Despite the large number of Iba1 positive cells, no evidence for co-expression
of EBERs was seen (figure 3.35). To furthur examine the phenotype of EBV infected
cells, we triple-stained for EBERs, Iba1 and GFAP (astrocytes marker), using
fluorescence in situ hybridization (FISH) and immunofluorescence (IF). IF staining
was validated for both cellular markers (Iba1 and GFAP) in case MS63 (figures 3.36
and 3.37), in which reactive gliosis was confirmed in autopsy report.
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Figure 3.35: Double staining of EBERs and Iba1 in case MS63. This case had gliosis
but no EBER co-expression. Occasional cells appeared double positive for EBERs
and Iba1. Original magnification 40x (a), 60x (b)

Figure 3.36: IF staining for Iba1 in case MS63. Iba1 marker does not discriminate
between monocytic blood-originated macrophages and CNS-resident activated
microglia [297] with phagocytic activity. Original magnification 60x
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Figure 3.37 IF staining for GFAP in case MS63. Abundant astrocytes with elongated
star-shaped projections. Some astrocytes are in contact with blood vessels. Beside
tight junctions and perivascular macrophages, astrocytes feet help maintain BBB
integrity
Using triple staining for EBERs (green), GFAP (blue) and Iba1 (red) in MS
brain tissue showed numerous round Iba-1 and star-like GFAP positive cells (figure
3.38). EBER-FISH resulted in significant amount of auto-fluorescence, which might
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be due to the long fixation, making detection of specific signals a challenging task.
Further studies are needed to determine whether EBV may infect microglia and
astrocytes in MS brain.

Figure 3.38 Triple staining in MS63. EBERs (green), Iba1 (red) and GFAP (red)
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Chapter 4: Discussion
"If you are asking the wrong question, or the right question in the wrong way, the
answer doesn't really matter." -Thomas Pynchon
The history of research done on determining what causes MS is long, and
various possible etiological agents have been implicated. MS is a complex polygenetic
disease that is associated with a number of intrinsic and extrinsic (environmental) risk
factors [77]. While controversies concerning an association between EBV and MS
have been around for over 3 decades, the virus continues to be the most strongly
associated risk factors for MS. The aim of this study was to verify and the delineate
role of EBV, if any, in MS pathogenesis. Association studies are complex and require
large sample size to draw valid conclusions. To meet this expectation, coronal brain
slices from autopsied 122 MS and non-MS control cases were used.
This thesis brought to light a number of potential technical solutions to
challenges in using tissue bank formalin archived brain slices. Thus, maximizing
research benefit from such material. Moreover, multiple aspects of the association
between EBV and MS were explored and results highlight potential contribution of the
virus in MS pathogenesis.
4.1 Maximizing Utilization of Long-Term Formalin Preserved Brain Tissues
Here we demonstrated that PCR inhibition could be overcome by using
optimized conditions of extraction. Our findings have confirmed results of previous
studies, which reported possible extraction of DNA of usable quality despite prolonged
fixation in formalin -for over 20 and even 40 years [298-303]. Interestingly, some
reports have described amplification of DNA fragments (from archival materials) that
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are over 400 bp long [300, 301]. Others on the other hand, reported amplification of
much smaller fragments [298].
While we have showed that using SDS in a concentration as low as 0.1% is
still effective in disrupting tissue homogenate and yet does not inhibit PCR as seen at
higher concentration (1%), others have suggested that SDS retains PCR inhibition even
at concentrations as low as 0.01% [304]. This difference could probably be due to
different tissues used. Nevertheless, early reports recommend using 1% SDS in
phenol/chloroform extraction of DNA from long time formalin fixed materials [303].
Another technical challenge emerged when using IHC. Formalin fixation
induces extensive protein cross-linking [270]. This causes masking of certain epitopes,
thus impeding immunorecognition by primary antibodies [305]. To enhance
immunoreactivity we optimized heat-induced antigen retrieval, taking into
consideration heating temperature, length of heating, and pH of antigen retrieval
solution. Although the mechanism of action of heat/pH-dependent antigen unmasking
is not fully understood, several reports have suggested using both high temperature
and high pH for formalin stored tissues [296, 305-307]. This is believed to promote
reversal of chemical modification of proteins caused by fixation. This also involves
protein inactivation and alteration of protein configuration, all of which lead to
releasing

protein

epitopes

and

increasing

tissue

antigenicity

and

thus

immunorecognition of target proteins [296, 305-307].
4.2 EBV is More Prevalent in MS than in Non-MS Cases
Our hypothesis that EBV may contribute to MS pathogenesis was tested, by
investigating EBV presence in the brain tissue of MS and non-MS cases. Two highly
sensitive viral detection methodologies (EBER-ISH and PCR), were employed in a
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large series of cases. Both methodologies pointed towards higher prevalence of EBV
in MS cohort than in controls (90% vs 24% respectively). EBV detection by PCR
depended on amplifying BamHIW fragment, whereas EBER-ISH, the ‘gold standard’
[156] and widely utilized approach in detecting EBV, targeted abundantly expressed
viral non-coding RNAs. In our hands EBER-ISH showed greater detection sensitivity
compared to PCR (83% and 64%, respectively). The lower sensitivity of PCR is most
probably due to poor quality/ quantity of DNA extracted from long-term formalin fixed
tissues. Hence, using both techniques helped in decreasing false negatives and
confirming results.
We further focused on the differential prevalence of EBV in brain parenchyma,
and we found overall EBV positivity in MS brain parenchyma reached 87.1% as
opposed to 23.8% in non-MS control cases. It is noteworthy that EBV was detected in
non-MS control cases which had neurological diseases including progressive
dementia, Alzheimer’s, progressive supranuclear palsey-like tauopathy, and
meningioma. EBV was absent in brain tissues from non-MS control cases with no
history of neurological conditions. This observation confirms results of two previous
studies where EBV infected cells were seen in the brain of control cases with
neurological conditions namely those with marked neuroinflammation (stroke), brain
lymphomas, meningitis and tuberculous meningoencephalitis [266, 308]. Moreover,
the number of infected cells in these cases was very low, often less than a dozen cells
[266, 308]. Whether EBV is universally triggered in CNS inflammation associated
conditions remains to be proven.
Similar to the pattern observed in our EBER positive cases, Tzartos and coauthors reported EBV infected cells scattered in brain parenchyma as well as close to
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and in perivascular cuffs [266]. This distribution specifically correlated with elevated
expression of inflammatory cytokine IFN-α [266]. Therefore, associating EBV
infection to specific anatomical pathology, requires further investigation of markers
associated with MS pathology, including mitochondrial exhaustion and oxidative
stress [309, 310], complement activation [45], disrupted blood-brain barrier (BBB)
[48, 311, 312], oligodendrocyte damage, and demyelination and remyelination [57,
313, 314], and the correlation of these markers with EBV infection.
Quantitatively, we detected EBV viral load in MS brain parenchyma with copy
numbers that varied between 157 to 16,823 EBV copies per microgram DNA, with
approximately 93% of the cases having a viral load below 2,000 copies per microgram
DNA. Thus, EBV viral load is rather low to moderate in MS brain parenchyma. As
mentioned above, these viral copy numbers could be partly affected by the quality of
DNA used. In contrast to this observation, Torkildsen and colleagues [315] reported
lack of quantitative evidence of EBV presence in MS brain. They suggested the need
for techniques with greater sensitivity to avoid false negatives due to limited number
of infected cells present in MS brain tissue that could be easily lost during tissue
processing for DNA extraction [315]. A potential reason for the discrepant findings is
that Torkildsen’s study quantitated transcripts of EBNA-1 and -2, LMP1 and BZLF1
using qPCR as well as IHC for EBNA and LMP in order to conclude EBV presence
or absence in the brain. Studies on EBV infection biology emphasizes that EBV
infection could be reliably determined based on detecting EBV genome using sensitive
methods [275] or abundantly expressed EBERs using EBER-ISH [156]. Therefore,
targeting other transcripts, the expression of which may or may not occur in certain
settings can yield false negatives. Two other studies also could not reach conclusive
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evidence of EBV presence in MS lesions [268, 269]. These studies used a small
number of cases (12- 20 blocks) to examine their hypotheses [268, 269]. In this study,
we have used 615 blocks from over 120 MS and non-MS cases to compensate low
statistical power in the previous studies.
We also tested the possibility that EBV prevalence in MS brain may be nonspecific, by screening for other common herpesviruses, namely HSV, CMV, and
HHV-6. Our data clearly indicates that EBV presence in MS is specific and selective,
since none of the other viruses examined were found in MS cases by PCR. A previous
study, however, reported the coexistence of EBV, HSV, HHV-6 and VZV DNA in MS
lesions [316]. EBV DNA was found only in ∼10% of MS lesions and other
herpesviruses were more prevalent in MS compared to EBV [316]. The authors
concluded that none of these herpesviruses could be specific for MS pathogenesis
[316, 317]. This study relied solely on PCR amplification of DNA from MS lesions,
and no other confirmatory independent tests were done.
4.3 EBV May Use Multiple Routes of Entry to the Brain
Compared to brain parenchyma, meningeal layers showed both less prevalent
and weaker EBV load using PCR and EBER-ISH. Histology and EBER-ISH staining
showed lack of meningeal inflammation in most of the cases. However, we did find
evidence of EBV infection in sections with pronounced meningeal inflammation, but
we could not localize ectopic B cell folicles which were repeatedly reported by Serafini
et al [263, 265, 308]. Similar to our findings, Kooi et al [290] reported lack of
widespread inflammation and/or tertiary lymphoid structures in meningeal layers
[290]. These finidings could be explained by an observation made by few other studies
showing heterogenous distribution/ occurrence of meningeal inflammation and ectopic
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lymphoid-like structure in MS (figure 4.1) [289, 291, 293]. These studies reported 3040% incidence of tertiary structures, commonly found in the deep sulci of the forebrain
from secondary progressive and primary progressive MS cases. Whereas cerebellar
meninges,

particularly

subarachnoid

space

(SAS),

had

mild

chronic

microglia/macrophage inflitration lacking lymphoid-like structures [289, 291, 293].
The degree of dissimination of immune infilitrates from meningeal layers was
determined by presence of tertiary lymphoid like structures and it appeared to impact
microglia activation and formation of cortical demyelinative lesions. Thus, athors
concluded the participation of meningeal inflammation in MS grey matter injury and
atrophy, which is aggravated by presence of tertiary lymphoid structure [289, 291,
293].

Figure 4.1: Immune cells in the brain. These cells buildup in white matter
perivascular spaces (A) and meningeal SAS [318]
While embryological growth of B cell follicles generates anatomically static
entities, namely secondary lymphoid follicles including several lymph nodes and
spleen, tertiary lymphoid follicles result from long-standing inflammation within
certain organs following aberrant tissue-specific autoimmune response. These tertiary
lymphoid structures, also known as B cell ectopic lymphoid follicles, have been seen
in a wide array of autoimmune disorders like rheumatoid arthritis, systemic lupus
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erythematosus and MS [318]. Based on immunostaining properties, tertiary lymphoid
structures are described as aggregation of chiefly CD20 positive B cells [308] and a
collection of other immune cells including Ig positive and/or CD138 positive plasma
cells, CD35 or CXCL13 positive follicular DCs, ki67 positive proliferating cells, and
CD3 positive T cells [318].
These aggregates exhibit characteristic germinal centre-like properties
including B cell expansion, differentiation into Ig producing plasma cells, and
abundance of folliclur DCs with specialized chemokine expression. What does not
give them a perfect germinal centre feature is absence of mantle zone and prevalence
of memory B cells and naturally occurring site [319]. Frequently reported CNS sites
for these germinal centre-like B cell aggregates are leptomeningeal SAS within deep
cerbral sulci and perivascular cuffs [265, 289, 308, 318, 319]. They may also occur at
lower frequency within inflamed brain parenchyma, but not within demyelinated or
chronic active lesions [318].
It should be noted that CNS tertiary lymphoid structures have been reported in
particular anatomical sites of the brain, such as cingulate and precentral gyri in the
frontotemporal, parietal and insular cortex. Also absence or rarity of tertiary structures
was reported in certain sites including external or inferior brain surface, cerebellum,
periventricular regions, brainstem and spinal cord [318]. We however, sampled
meningeal tissues from randomly selected areas, and with no pre-determined
preference to any specific regions. Our samples (coronal brain slices) were highly
heterogenous and represented a wide array of brain regions, different age at both
disease onset and death, gender, MS type and lesion type. These factors could justify
poor prevalence of brain tertiary lymphoid structures in our study. Moreover, the
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delicate nature of meninges necessitate gentle cutting during tissue sampling and
cautious treatment in paraffin blocking and staining. Therefore, we cannot eliminate
the possibility of false negative in some of our cases resulting from inevitable harsh
procedures.
Although it was suggested that B lymphocyte-rich tertiary lymphoid structures
within meningeal layers could be the main territory of EBV persistence and
reactivation contributing to MS pathology, [262, 319], we could not demonstrate that
meninges were the exclusive route of EBV entry to the brain. The majority of
meningeal blocks were devoid of substantial immune infiltrate within intact meningeal
layers. Hence, in addition to inflammed meninges, EBV could probably take various
routes to the brain. We noted EBV infected cells within or in close proximity to
inflamed perivascular cuffs [264]. Although this was not preferential, BBB endothelia
could potentially be a divergent route for EBV to utilize in reaching its destination, the
inflammed brain. This notion is supported by reports demonstrating that human brain
microvascular endothelia is permissive for EBV infection [320]. We, however, did not
furthur explore the likelihood of EBV entry via BBB endothelium, so it remains a
possibility that requires furthur investigation. It is worth asking whether EBV infected
cells transmigrating across the endothelial layer triggers an immune response by
cytotoxic CD8+ T cells, as seen within meningeal ectopic structures and contributes
to cortical plaques genesis.
4.4 EBV Can Maintain a Latent Infection or Induce a Lytic Cycle in the Brain
We divided our cases into 3 categories based on number of EBV positive cells.
While majority of the cases (40 cases) had between 1 to 49 positive cells, 29 cases had
intermediate positivity (50-200 positive cells), and 19 cases were heavily infected
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(over 200 positive cells). It has been shown that detecting EBV latent nuclear protein
EBNA1 and early lytic BZLF1 requires at least 0.01% to 0.1% EBV infected cells
[315]. Thus, we immunostained heavily infected cases to capture a global view of the
nature of EBV infection in MS brain. While some studies have not found evidence of
lytic or latent infection [315, 321], our results suggested that a proportion of EBV
infected cells undergo lytic, (defined by BZLF1 immunoreactivity) and latent
(manifested by EBNA1 immunostaining) infection. Consistent with our findings is
the results of several independent studies [262, 264-266]. Recently it was shown that
EBV infection of human brain microvessel endothelial cell lines was accompanied by
the expression of a limited set of latent and lytic genes, including BZLF1 and EBNA1
[320]. We found that EBNA1 expression was more common (~78% vs ~17% of tested
cases) and higher (~1-10% of EBER positive cells vs ≥ 1%) than BZLF1 expression.
Earlier reports demonstrated dominance of latency type II phenotype in MS brain by
showing increased immunoreactivity for LMP1 and LMP2A, and less frequently for
EBNA2 [264]. We also noted increased cellularity in parenchymal regions containing
EBNA1 expression. This hypercellularity could be an immune response triggered by
observed viral gene expression. We suggest that cases showing notable expression of
lytic genes could experience infiltration of cytotoxic CD8+ T cells. Some earlier
reports have indicated EBV lytic cycle provokes disturbed immune response,
particularly from perforin- and granzyme B-secreting cells [262, 264, 265].
4.5 Beside B Cells, EBV May Infect Some CNS-Resident Cells
Apart from occasional cells, we were not able to find broad infiltration of CD3
positive and CD20 positive cells in most of the brain sections heavily infected with
EBV. Scarce B cell infiltration observed in our cases is in accordance with the findings
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of another recent study [315]. We did however find presence of increased CD20
positive cells in one case where inflamed perivascular cuffs dominated. Others
reported notable infiltration of CD20 positive cells into brain parenchyma as well as
within meningeal layers [319, 322]. These studies reported marked presence of B cells
particularly in progressive MS brain. This clinical type of MS could be underrepresented in our study. Also, it may be possible that B cell population in our samples
had long-lasting plasma cell phenotype, which are CD20 negative [323].
Correlating the number of EBER positive cells with CD20 positive cells, we
found that number of cells stained for EBERs was much higher than that of cells
stained for CD20. This indicated that despite low infiltration of B cells in brain
parenchyma, EBV infected cells were conspicuously present. We further confirmed
these findings by staining for both markers, CD20 and EBERs. Some cells coexpressed both markers, but others were single positive for either CD20 or EBERs.
This meant that EBV infection could potentially occur in other types of cells.
Previously it was shown that EBER positive cells in the brain accumulated in IFN-α
secreting microglia [266]. We stained for microglia, astrocytes markers and EBERs,
but our results were not conclusive. This, however, does not eliminate the possibility
of EBV infecting other types of cells in MS lesions. It has been suggested that a link
between CNS microglia, EBV and human endogenous retroviruses W family and MS
associated retroviral elements (HERV-W/MSRV) exist in triggering oligodendrocytes
injury in MS [125, 130, 324, 325]. Increased expression of these retroviral elements,
particularly env protein within microglia or astrocytes is thought to be instigated by
EBV-induced HERV-W reactivation [125, 130, 324, 325].
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Furthermore, BAFF, a member of TNF family contributing to maintaining B
cell survival, has been shown to be produced in MS lesions by astrocytes (analogous
to stromal cells in lymphoid tissues), and induce longevity of CNS infiltrating B cells
and plasma cells that express BAFF marker [326]. This indicates an intimate
interaction between astrocytes and B cell (figure 4.2), which could be infected, and
raises questions regarding EBV spreading to these astrocytes [326].

Figure 4.2: Close interaction between astrocytes and plasma cells. This interaction
supports maintenance of long-lived B cells in MS lesions influenced by different
chemokines and cytokines [326]
4.6 Proposed Mechanism for the Contribution of EBV in MS Pathogenesis
Several hypotheses have been proposed to explain potential mechanisms that
EBV may use to precipitate autoimmune response. These mechanisms include epitope
spreading, molecular mimicry or cross-reactivity between EBV antigens and selfantigens, EBV-induced immortalization of ‘encephalitogenic’ B cells that secrete CNS
antigens-reactive antibodies and present CNS antigens to encephalitogenic T cells, IMinduced activation of EBV-specific T lymphocytes causing bystander damage to CNS
and mistaken self [228, 327]. With the available date about known MS pathology, no
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hypothesis has yet proved perfect to explain all identified pathological aspects of the
disease.
The strong sero-epidemiological evidence linking EBV to MS, which is not
seen with other viral agents points to genuine contributory link to MS. If EBV infected
cell infiltration to the brain was a sequelae of hyper-immunity accompanying MS
inflammation, we would have seen an evidence of infiltration of other human
ubiquitous viruses into the brain, which we could not demonstrate in here. Also reports
of developing MS in patients with history of infectious mononucleosis (IM) indicates
that EBV is not a passive bystander in MS but actively participates toward MS genesis
[235]. Based on previous findings in line with our results, we propose the following
events for a role of EBV in MS pathogenesis.
1- IM and MS risk associated alleles polarize the immune response toward
inflammatory phenotype, and unstable response from EBV-specific lymphocytes
that partially lose control of EBV regulation, hence the elevated levels of antiEBNA immune response preceding MS onset [240]. Due to EBV immortalization
of B cells, and deficient antiviral CD8+ T cells response, EBV triggers a
longstanding dysregulated immune response.
2- In molecular mimicry, epitopes of EBV antigens are believed to share common
structure to CNS antigens. Thus, EBV-specific lymphocytes can recognize CNS
antigens and mount autoimmune response. EBNA1 has been shown to share
homologous structure to myelin antigens. Through molecular mimicry EBV could
induce development of CNS antigens-reactive lymphocytes, which through
transiently disrupted BBB and in response of various chemoattractants,
transmigrate across BBB endothelia.
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3- EBV infected B cells breach BBB with other brain-infiltrating lymphocytes.
During this immune trafficking event, EBV infects a fraction of endothelial cells
of brain small blood vessels probably stimulating secretion of more
chemoattractants and cytokines for additional chemotaxis.
4- Our results suggest that EBV infection may also involve some CNS-resident cells
such as microglia and astrocytes. If that is the case, then EBV infection can induce
these cell to secrete chemoattractant soluble factors into SAS and intrathecal
compartment causing influx of wide array of lymphocytes into meningeal layers
forming tertiary lymphoid structures, which in turn participates in subpial cortical
demyelination. Infecting microglia could also induce their activation and
subsequently participate in endogenous injury to nearby oligodendrocytes and loss
of axons [57].
5- Within the brain, EBV could activate specific sequences of HERV-W/MSRV in
situ to further contribute to MS pathology.
4.7 Concluding Remarks, Limitations, and Future Research
In conclusion, the extensive study in this Masters thesis highlighted several key
findings: (i) EBV infection preferentially occurs in MS lesions, and may
fundamentally contribute to the inflammatory nature of the disease, (ii) besides
meningeal route, EBV may exploit other disrupted routes to access the inflamed brain,
(iii) EBV infection tends to induce latent cycle more frequently than lytic cycle, but
this may primarily depend on lesion type as suggested by earlier studies [263, 264]
and (iv) there is an indication of EBV infection occurring in cells other than typical B
lymphocytes. We suspect some CNS-resident cells may be involved. By providing
additional evidence that EBV infection can occur preferentially in MS brain and in
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frequencies that are higher than to be just an arbitrarily coincident finding, the casecontrol study in this thesis adds to the growing body of evidence and supports a
contributory association between EBV infection and MS pathogenesis.
Since some studies failed to find an association between EBV and MS, a
number of potential reasons could cause the discrepant findings reported by different
studies. Most of these studies used a small number of cases. Reproducibility of studies
outcome is highly dependent on sample size [328], and type II error are likely to occur
in small sample size studies. Thus, screening large number of cases, where every single
case is represented by multiple blocks and many series of sections (figure 4.3), could
in part reduce inter-studies variability.

Figure 4.3: EBV infected cells in MS brain. Previous reports suggested specific
anatomical distribution of EBV infection in MS brain [329]
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Moreover, inconsistencies in tissue processing and means of viral detection and
sensitivity of the methodologies employed, could greatly influence the results [308].
In this study we targeted EBV small non coding RNAs (EBERs) to localize EBV
infected cells in MS brain. EBERs are expressed in substantial amounts, up to 107
copies per infected cell. EBER2 expression is ten folds less than EBER1, however both
are expressed in all latently infected cells [138]. Thus, designing probes that
specifically target both EBERs together rather than targeting only single EBER
increases the sensitivity of EBV detection approach [156]. Because EBERs are not
expressed during viral replication [330], to determine occurrence of EBV lytic
infection, lytic antigens should be targeted, for instance by immunostaining or using
reverse-transcriptase PCR [264]. Tissue processing is of great importance, because
tissue exposure to RNA-denaturing conditions or agents could result in false negatives
in EBER-ISH [308, 331]. Hence, observing good-quality yielding protocols and
ensuring maintained cellular and molecular integrity throughout tissue processing will
help eliminate EBER false negatives [332]. There have been reports of infrequent but
different pattern of EBER staining in the brain by Aloisi et al [308]. Despite the
dominance of typical nuclear EBER stain, some cells showed specific cytoplasmic
stain in the brain, explained by EBERs release from the nuclear compartment, and this
pattern could be a reflection of long-standing EBV infection [308]. These same factors
are also applicable to other EBV detection techniques including IHC for EBV proteins
and PCR amplification of EBV DNA. For IHC, tissue antigenicity should be carefully
examined as many of the epitopes are masked in formalin fixed tissues [283] and
recovery of immunoreactive epitopes is a matter of choosing optimal antigen retrieval
protocols [333] and including suitable control tissues and control antibodies [263].
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Collectively, tissue processing, and immunostaining procedures along with selecting
primary antibodies recognizing retrievable EBV epitopes affect results of IHC [308,
332]. Lastly, applying PCR to detect EBV nucleic acids, as we have shown here [275],
largely depends on isolating amplifiable quality of DNA/RNA. Also variation in
frequency of EBV infected cells in the brain is expected, so extracting DNA/RNA
from an area where infected cells represent a minute proportion of the whole area,
could lead to false negative PCR results. Therefore, applying different confirmatory
methodologies is essential to reduce the likelihood of false negatives [308, 332].
The study in this thesis has a number of limitations that could be summarized
as follows:
1- We successfully utilized long-term formalin fixed materials in exploring many
aspects of our hypothesis. Unlike fresh samples, formalin fixed tissue is not
optimal for many molecular studies, such as reverse-transcriptase PCR due to
extensive degradation that takes place in the presence of formalin fixation.
Furthermore, immunofluorescence staining of formalin fixed tissues can also lead
to autofluorescence that makes visualizing markers of interest difficult.
2- In our study, we only examined the presence of EBNA1 and BZLF1 as indicators
of EBV lytic and latent infection, respectively. Using additional antibodies
targeting other EBV antigens could help further characterize observed latent and
lytic infection. Different latency programs could be distinguished by screening for
presence/absence of expression of latent antigens EBNA2, LMP1 and LMP2.
Also, different stages of EBV replicative cycle can be demonstrated by staining
for early lytic BFRF1, BMRF1 or late lytic p160, gp350 proteins.
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3- We focused on a few cellular marker, namely B cells, microglia and astrocytes
marker to phenotypically characterize EBV infected cells. Testing a larger panel
of cellular markers can be more informative for determining which cells are
infected with EBV in MS brain.
Based on these limitations, we think future studies should emphasize the
biology of EBV infection in MS brain. This involves addressing questions such as
what possible routes does the virus take to enter the brain? What events precede viral
entry into the brain? What determines the occurrence of EBV infected cell-rich tertiary
lymphoid structures in the brain? Does EBV possess sufficient ability to infect cells
other than B lymphocytes? And if that is the case, how does that disturb host-virus
homeostasis and what is the patho-molecular pathway for interaction between different
EBV infected cells in contributing to MS pathology? Lastly, it has been shown that
EBV interacts with various other genetic and environmental risk factors such as HLA
class II alleles, vitamin D receptor, smoking and HERV-W/MSRV in MS
pathogenesis. Can future research draw a scheme of such an interaction towards MS
pathogenesis? Will such an interaction be able to explain different pathological
features of MS including intrathecal Ig oligoclonal bands and early axonal loss?
In summary, in this study we hypothesized a possible contributory role of EBV
infection in the brain in MS pathogenesis. Subsequently we presented experimental
evidence based on several different methodologies and approaches to indicate that
EBV is involved, directly or indirectly in the pathogenesis of MS.
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Appendix
Appendix I: Demographic and Clinical Data of MS and Control Cases
Case
Ctrl1

Age
55

Sex
F

Ctrl2
Ctrl3

25 wks
50

M
M

Ctrl4
Ctrl5

37.5 wks
73

M
M

Ctrl6
Ctrl7
Ctrl8
Ctrl9
Ctrl10
Ctrl11
Ctrl12
Ctrl13
Ctrl14
Ctrl15
Ctrl16

55
N/A
N/A
N/A
N/A
N/A
69
38
42
68
49

M
M
M
M
F
M
M
F
M
M
F

Ctrl17

50

M

Ctrl18

76

M

Ctrl19
Ctrl20
Ctrl21
MS1
MS2
MS3
MS4
MS5
MS6
MS7
MS8
MS9
MS10
MS11
MS12
MS13
MS14
MS15
MS16
MS17
MS18
MS19
MS20
MS21
MS22

63
74
N/A
43
74
79
52
48
69
74
48
57
50
68
61
67
80
58
77
61
63
68
N/A
81
32

F
M
N/A
M
M
F
F
M
F
F
M
M
M
F
F
F
M
M
F
F
F
F
F
F
F

Cause of death/ remarks
Extensive end-stage long-standing interstitial lung disease with
secondary RSV infection
Immature lung development
Multifactorial: severe interstitial lung disease with honeycombing,
cor pulmonale, 3rd degree heart block (MI)
Stillborn infant: Intrauterine foetal death due to placental infarction
Acute bronchopneumonia: secondary to metastatic transitional cell
carcinoma of bladder, metastatic to the lungs, liver & vertebra
Alcohol induced cirrhosis
Dementia with AD
Acute MI
MI with emphysema
Nodular sclerosing Hodgkin's
Progressive dementia with AD
Respiratory distress due to acute bilateral pneumonia
Massive GI haemorrhage secondary to idiopathic FHF
FHF with HSV hepatitis & haemorrhagic necrosis + DIC
Definite AD - slowly progressive dementia
Severe intra-abdominal haemorrhage post liver biopsy, coagulopathy
associated with chronic hepatic failure (cryptogenic cirrhosis &
hepatitis)
Multiorgan failure secondary to ischaemic cardiomyopathy (severe
CHF)
Ventricular fibrillation secondary to Ecoli septicaemia (septic shock).
Multiple small bowel adhesions, perforations & obstructions
Widely metastatic ovarian adenocarcinoma stage IIIc
Dementia. Progressive supranuclear palsey-like Tauopathy
Meningioma
Severe chronic active & inactive MS
Moderately severe chronic inactive MS
Chronic inactive MS. Arteriosclerosis
Chronic inactive MS
Moderately severe chronic active MS
Chronic inactive MS
Chronic inactive MS
Subacute MS: involving cervical spinal cord
Chronic inactive MS
Chronic active SPMS
Moderately severe chronic inactive MS
Mild chronic inactive
Moderately severe chronic inactive MS. >20-yr course
Severe chronic inactive MS: affecting spinal cord
Chronic active smoldering & chronic inactive
Chronic inactive SPMS: affecting spinal cord
Severe chronic inactive MS
Chronic inactive SPMS: severely affecting cervical spinal cord
Chronic inactive MS
Multiple active & reactivated MS plaques
Moderately severe chronic inactive RRMS
Severe chronic progressive MS
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MS23
MS24
MS25
MS26
MS27
MS28
MS29
MS30
MS31
MS32
MS33
MS34

46
77
77
78
N/A
41
50
70
54
87
70
N/A

F
M
F
F
M
F
M
F
M
F
M
M

MS35
MS36
MS37
MS38
MS39
MS40
MS41
MS42
MS43
MS44
MS45
MS46
MS47
MS48
MS49
MS50
MS51

52
67
54
69
75
58
60
53
50
65
92
59
59
43
59
53
56

M
F
F
F
F
F
F
F
F
F
F
M
M
M
M
F
F

MS52
MS53
MS54
MS55
MS56
MS57
MS58
MS59
MS60
MS61
MS62
MS63
MS64
MS65
MS66
MS67
MS68
MS69
MS70
MS71
MS72
MS73
MS74
MS75
MS76
MS77
MS78

29
76
42
67
65
42
98
77
79
66
70
32

F
F
M
M
F
M
M
F
M
M
F
F
F
F
F
M
F
F
F
M
F
F
M
M
F
F
F

60
57
70
56
75
71
45
57
66
75
59
60
61
65

Progressive MS
Moderately severe chronic inactive MS
Chronic inactive MS coexisted with AD
Moderately severe chronic inactive MS (38-yr course)
Moderately severe chronic active MS (30-yr course) COD: PE
Chronic inactive MS
Chronic inactive MS
Chronic inactive MS
Chronic inactive MS
Chronic inactive spinal MS. Arteriolosclerosis
MS (19-yr course)
Moderately severe chronic inactive MS. Arteriolosclerosis, cranial
bleed
Moderately severe chronic inactive MS
Progressive MS
Severe chronic inactive MS (25-yr course)
Chronic inactive MS
Chronic inactive MS: affecting spinal cord. COD: respiratory failure
Chronic inactive MS (20 yr course). Atherosclerosis, arteriosclerosis
Chronic inactive MS
Moderately severe chronic inactive MS
Moderately severe chronic inactive MS
Very minimal demyelinative MS plaque burden
Moderate chronic inactive MS. Arteriolosclerosis
Moderately severe chronic inactive MS. Atherosclerosis
MS- no further information available
Chronic inactive with chronic active smoldering MS
Chronic inactive MS
MS- no further information available
Severe chronic inactive PPMS, (40-yr course). Idiopathic
Parkinsonism
MS- no further information available
MS- no further information available
MS- no further information available
MS- no further information available
MS- no further information available
MS- no further information available
MS- no further information available
MS- no further information available
MS- no further information available
MS- no further information available
MS- no further information available
Chronic inactive noninflammatory RRMS, PML
MS- no further information available
MS- no further information available
Chronic active MS
MS- no further information available
MS- no further information available
MS- no further information available
MS- no further information available
Severe spinal mixed chronic inactive & active MS (10-yr). PML
MS- no further information available
MS- no further information available
MS- no further information available
Moderately severe chronic active MS
MS- no further information available
MS- no further information available
MS- no further information available
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MS79
MS80
MS81
MS82
MS83
MS84
MS85
MS86
MS87
MS88
MS89
MS90
MS91
MS92
MS93
MS94
MS95
MS96
MS97
MS98
MS99
MS100
MS101

61
84
71
71
61
62
63
74
65
89
70
46
59
69
70
64
60
56
67
67
74
77

F
F
F
F
M
M
F
F
F
F
M
F
F
F
F
F
F
F
M
F
F
F
F

Severe chronic active smoldering MS
MS- no further information available
MS- no further information available
MS- no further information available
MS- no further information available
MS- no further information available
Chronic inactive SPMS
Chronic inactive MS
MS- no further information available
MS- no further information available
MS- no further information available
MS- no further information available
MS- no further information available
MS- no further information available
MS- no further information available
MS- no further information available
MS- no further information available
MS- no further information available
MS- no further information available
MS- no further information available
MS- no further information available
Chronic inactive SPMS with superimposed relapses
MS- no further information available

Appendix II: Buffers and reagents preparation
A- Preparation of hybridization buffer
Five millilitre hybridization buffer was prepared by mixing:
1- 2.5ml formamide deionized (Sigma Cat# F9037),
2- 1ml 25% dextran sulphate (Sigma Cat# D8906),
3- 500µl 20x SSC (saline sodium citrate, pH7.0. 1L: 175.3g NaCl (3 M) + 88.2g
sodium citrate + 800mL sterile dH2O),
4- 125µl 2M Tris-HCl pH 7.5,
5- 875µl ddH2O.
B- Preparation of 10xPBS (phosphate buffered saline):
10x in 1L ddH2O: 80g NaCl, 2g KCl, 14.4g Na2HPO4, 2.4g KH2PO4; pH 7.4.
C- Preparation of DAB:
One gram of DAB powder was dissolved in 40 ml water with ~5 drops of HCl
(ACS reagent, 37% , Sigma, 258148) to facilitate DAB dissolving.
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Appendix III: Coating slides
D- Coating histology slides:
1- Slides were washed in water for 30 minutes
2- Slides were immersed in acetone (Panreac, 361007) for 5 minutes
3- Slides were incubated in 2% 3-aminpropyltriethoxysilane in acetone for
another 5 minutes
4- Slides were rinsed in distilled water for a minute and eventually left to air
dry overnight
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